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THE EXPANSION OF FDA’S ENFORCEMENT POWERS FROM 1906-2003
BRIEF HISTORY OF THE FDA
The Food and Drug Administration of the Health and Human Services Department is the largest American
regulatory agency. Its regulatory authority covers most food products (other than meat and poultry), human
and animal drugs, therapeutic agents of biological origin, medical devices, radiation-emitting products for
consumers, medical, and occupational use, cosmetics and animal feed. The FDA regulates over $1 trillion
of products a year (25% of all money spent in the USA). “The basis for the FDA and the expansion of
its powers follow a shift in American economic focus from the pro-industrial growth that dominated the
19th century to the pro-consumer health standards that is a cornerstone of 20th century American economic
development.”1
The Pure Food and Drug Act of 1906 (1906 Act) was enacted to prevent the manufacture, sale or trans-
portation of adulterated or misbranded foods, drugs, medicines and liquors. It vested enforcement power
in the Bureau of Chemistry, of the U.S. Department of Agriculture. In July 1927, the non-regulatory re-
search functions of the bureau were transferred to a diﬀerent segment of the department and the Bureau
of Chemistry was renamed as the Food, Drug and Insecticide Administration.2 That name was eventually
reduced to the Food and Drug Administration (FDA) in July1930. 3 The FDA was transferred from the
U.S. Department of Agriculture to the Federal Security Agency in June 1940.4 In 1953, the Federal Security
1Zaltman, Haim, “Legal Purpose, Risk Stimulators, and Foreign Investment: A Comparative Legal Analysis of the American
and Russian Experiences.” (2001), http://www.iet.ru/guest/zaltman/dis.htm
2Swann, John P., Ph.D., History of the FDA, FDA History Oﬃce (adapted from George Kurian,
ed., A Historical Guide to the U.S. Government (New York: Oxford University Press, 1998)),
http://www.fda.gov/oc/history/historyoffda/fulltext.html.
3Id.
4Id.
1Agency was turned into the Department of Health, Education and Welfare (HEW).5 The education aspect
of HEW was extricated in May 1980, to form the Department of Health and Human Services, which is where
the FDA is currently located.6 In 1938, Congress passed the Food Drug and Cosmetic Act (FDCA) which
partially repealed the 1906 Act. This paper focuses on the expansion of the enforcement powers granted to
the FDA beginning with the 1906 Act, through the FDCA and the subsequent amendments to the FDCA.
It also discusses the treatment of FDA’s enforcement functions in courts.
Congress tends to pass acts expanding the FDA’s regulatory authority following “outrageous industry prac-
tices, public health tragedies, or signiﬁcant scientiﬁc advances.”7 Prior to the passage of the 1906 Act, the
practices of the food industry produced food that was unsafe and tainted.8 Upton Sinclair’s description of
the hideous condition of the meat-packing industry in The Jungle began a turmoil over tainted meat,9 which
was a very important factor in moving Congress to pass a meat inspection law and the 1906 Act.10
ENFORCEMENT POWERS OF THE 1906 FOOD AND DRUG ACT
Very few enforcement powers were provided in the 1906 Act to enforce the act. The Act provided the au-
thority to bring legal proceedings against violators of the Act’s provisions.11 These could be brought by any
district attorney to whom the Secretary of Agriculture reported any violations of the act.12 Violations of
the provisions against the manufacture, sale and transportation of adulterated food and drugs constituted
misdemeanors.13 The Act included the authority to promulgate uniform rules and regulations to enforce its
5See Wallace F. Janssen, The U.S. Food and Drug Law: How It Came; How It Works, 35 Food Drug Cosm. L. J. 132,
134 (1980).
6Swann, supra note 2.
7Ann Mileur Boeckman, Comment: An Exercise in Administrative Creativity: The FDA’s Assertion of Jurisdiction Over
Tobacco, 45 Cath. U. L. Rev. 991, n.1 (Spring, 1996).
8Id. at n.1, (quoting C.C.Regier, The Struggle for Federal Food and Drugs Legislation, 1 Law & Contemp. Probs. 3, 7-8
(1933) (describing sausages and hamburger steak that contained boracic acid in amounts approaching ﬁve to ten times that of
a typical medical dosage)).
9James Harvey Young,, The Pig That Fell Into The Privy: Upton Sinclair’s The Jungle and The Meat Inspection Amend-
ments of 1906, in Bulletin of the History of medicine 59, 467-80 (1985).
10Swann, supra note 2.
11Pure Food and Drug Act of 1906 Act, Pub. L. No. 59-384, § 5, 34 Stat. 768 (1906) (repealed 1938).
12Id.
13Id. at § 1 and 2.
2provisions. It vested this rulemaking authority in the Secretary of the Treasury, the Secretary of Agriculture
and the Secretary of Commerce and Labor.14 The Act authorized the Bureau of Chemistry to examine
specimens of foods and drugs.15 Any violations found would be reported by the Secretary of Agriculture
for prosecution. The act authorized seizure of any article of food, drug or liquor in interstate commerce,
or being warehoused after interstate transportation, that was found to be adulterated or misbranded.16 Fi-
nally, the Act authorized the Secretary of the Treasury to refuse admission into the U.S. any foods or drugs
being imported into the U.S., upon a ﬁnding by the Secretary of Agriculture that they were adulterated
or misbranded.17 Further, charges for storage and labor on goods that were refused admission were to be
paid by the owner of those goods. A default of such payment was to constitute a lien against any future
importation made by such owner.18
SHORTCOMINGS OF THE 1906 FOOD AND DRUG ACT
The 1906 Act was ridden with deﬁciencies in the enforcement powers that it provided for its enforcement.19
The original 1906 Act proscribed “false or misleading statements on the labels of foods and drugs.20 In
the ﬁrst test case to reach the Supreme Court, Johnson v. U.S.,21 the Court ruled that the prohibition
against false and misleading statements only related to the identity of the product and not to its curative
properties.22 This ruling encouraged manufacturers who had began to bring their labels into compliance
with the 1906 Act to revert to making false therapeutic claims on their product labels.23 In 1912, Congress
enacted the Sherley Amendment to the 1906 Act outlawing false therapeutic claims for patent medicines, but
14Id. at § 3.
15Id. at § 4.
16Id. at § 10.
17Id. at § 11.
18Id.
19See Ruth deforest Lamb, American Chamber of Horrors: The Truth About Food and Drugs (New York: Farrar and Rinehart
1936) for an analysis of the substantive shortcomings of the 1906 Act. Ruth De Forest Lamb was FDA’s chief educational oﬃcer,
who organized consumer support for the FDCA.
20Pub. L. No. 59-384, § 8, 34 Stat. 768 (1906)
21221 U.S. 488, 506-507 (1911).
22Lamb, supra note 19, at 12.
23See id.
3requiring the government to prove that the promoter intended to defraud his victim.24 The problem with
this intent to defraud requirement was that so long as violators demonstrated that they subjectively believed
their false curative claims, they could not be proceeded against.25 This presented a big obstacle to the
FDA’s eﬀorts at prosecuting violators, as it meant that the FDA had no real control of the package-medicine
industry. Furthermore, since violators of this provision were assessed very light penalties, they seemed to
view the penalties as “license fees for carrying on an illegitimate business.”26
Another problem with the 1906 Act was that, while it required the listing of certain addictive substances on
drug labels, it did not require enough additional information to make those statements meaningful to the
average person.27 Thus, drugs taken according to directions could be harmful but out of FDA’s reach. An ex-
ample of this is a case that the FDA investigated that involved a woman who had taken a headache medicine
made of a coal-tar derivative. She had ingested a powder containing six grains of acetanilid, followed soon
afterwards by a similar dose. The average dose of acetanilid prescribed by physicians is three grains. Her
death was instantaneous.28 The FDA could not proceed against the manufacturers of this product, because
it was labeled truthfully and the quantity of acetanilid was indicated on the label in accordance with the
law. The FDA’s sole recourse was to warn the public about such “remedies” and encourage them to read
the labels.29
Even for products that made false therapeutic claims that the FDA would have no diﬃculty proving that
they were made with fraudulent intent, the manufacturers found a loophole by which they could escape
FDA enforcement action. Manufacturers would simply make the curative claims in advertising, rather than
making them on the package.30 This left the FDA with no recourse at all against such products and their
24Janssen, supra note 5 at 135. See also The Sherley Amendment, ch. 352, 37 Stat. 416 (1912)
25Janssen at 135
26Lamb, supra note 19, at ix.
27Id. at 81.
28Id. at 81-82.
29Id. at 81-82
30See id. at 109-114, for a discussion on how the manufacturer of Crazy Water Crystals circumvented the FDA’s enforcement
4manufacturers.
The 1906 Act authorized the Secretary of the Treasury, the Secretary of Agriculture and the Secretary of
Commerce and Labor to make uniform rules and regulations for the enforcement of the Act.31 However,
the Act did not authorize the Secretary to establish legal standards for the regulated products, or tolerance
standards for poisonous residues in produce, choosing to let courts and juries handle that undertaking.32
The courts however were not interested in taking up this responsibility.33 They however did not accord
FDA regulations legal eﬀect. A frustrated David F. Houston, Secretary of Agriculture, remarked in his ﬁrst
Annual Report,
“The establishment of legal standards for judging foods would render the food and drugs act more
eﬀective, less expensive in its administration, and supply needed legal criteria. Under the present
conditions it is necessary in the individual prosecution to establish by evidence a standard for each
individual article. This procedure is very expensive, and sometimes its cost is out of proportion to its
value. Moreover, it may result in lack of uniformity in diﬀerent jurisdictions. With legal standards
established, the control of foods would be more uniform and measurably less expensive. The lack of
such standards is today one of the greatest diﬃculties in the administration of the food and drugs
act.”34
In 1914 Secretary Houston revived the Food Standards Committee to provide advisory criteria for what con-
stituted economic adulteration forbidden by the 1906 Act.35 These did not have the force and eﬀect of law
and thus the government still had to introduce several witnesses to testify as to the standards expected by
consumers and recognized by the reputable majority of the trade.36 In1923, Congress enacted a legislation
that established a legal standard for butter, for purposes of the enforcement of the1906 Act.37 Congress is
eﬀorts through advertising.
31Pub. L. No. 59-384, § 3, 34 Stat. 768 (1906)
32See Lamb, supra note 19, at 146-147, for a discussion on the food lobby’s successful eﬀorts at preventing the 1906 Act from
granting the Secretary of Agriculture authority to establish legal standards.
33See id. at 149, quoting the court’s opinion on determination of the appropriate standard for milk fat in ice-cream, in a case
against an Arizona ice-cream manufacturer, “It should not be left, it seems to me, for the decision of the court, but should be
determined by Congress or by authorization of the Secretary so that the trade may know...”
35Id. at 154
36Id. at 154-155.
3742 Stat. 1500 (1923) - butter was described as “the food product usually known as butter, and which is made exclusively
from milk or cream, or both, with or without common salt, and with or without additional coloring matter, and containing not
less than 80 per centum by weight of milk fat, all tolerances having been allowed for.”
5however not the appropriate body for setting legal standards generally for two reasons. First, it is such a
tremendous undertaking that no Congress could manage it.38 Second, technological advances would require
changes in the standards from time to time and these could only be eﬀected through Congressional action,
a slow process, which would render the standards inﬂexible.39 The lack of authority to promulgate legal
standards was indeed one of the greatest shortcomings of the1906 Act.
Imitations of certain standard products sold under the name of the standard product were considered mis-
branded and thus proscribed by the 1906 Act.40 However there was a loophole through which imitation
products escaped regulation under the 1906 Act: imitations were exempted from prohibition if they are
sold under their own distinctive names, as long as they did not contain any added poisonous or deleterious
ingredients.41 Some of these exempted products even though not poisonous, amounted to economic adul-
teration.42 The 1906 Act had no provision requiring the declaration of these products’ ingredients (unless
they included addictive substances), in proportion, so that the consumer would have suﬃcient information
on the label to make a well-informed choice.43
The 1906 Act authorized the FDA to regulate food that was adulterated because it was ﬁlthy, decomposed
or had in it any portion of an animal unﬁt for food.44 Enforcement oﬃcials were aware that unsanitary
conditions at the manufacturing plants meant that the ﬁnished product had to be contaminated.45 They
however had no authority to inspect these manufacturing plants. Since their jurisdiction began only when
the ﬁnished product entered interstate commerce they were limited to examining samples taken from actual
38See Lamb, supra note 19 at 147.
39Id.
40Pub. L. No. 59-384, § 8, 34 Stat. 768 (1906).
41Id.
42See Lamb, supra note 19 at 160-161, for a discussion on the economic adulteration worked by the addition of colored
soya-bean ﬂour to plain macoroni to change its color so it can look like the more expensive semolina macoroni, to extract more
money for it.
43Id. at 164.
44Pub. L. No. 59-384, § 7, 34 Stat. 768 (1906).
45See Lamb, supra note 19, at 252.
6interstate shipments.46 The methods available at the time were not sophisticated enough to detect invis-
ible ﬁlth.47 A method of micro-analyzing butter was innovated and an examination of butter that looked
perfectly clean to the naked eye revealed ﬁlth suggesting contamination from way back in the farm: hay,
chicken feathers, maggots, beetles, rodent hairs, ﬂy legs, cockroaches, metallic ﬁlings, etc.48 Butter that was
found to be adulterated in this way was sometimes released for renovating at the discretion of the courts.49
There was a special law regulating the manufacture and sale of renovated butter and oleomargarine.50 The
manufacturers of renovated butter or oleomargarine were required to be licensed and to use prescribed labels
and containers. The Bureau of Dairy Industry was responsible for the sanitary inspection of these factories.
The FDA did not have general inspection authority and it was thus diﬃcult to administer the ﬁlth provi-
sions of the 1906 Act. In 1934, the Shrimp Amendment to the 1906 Act was passed, authorizing supervisory
inspection of the seafood industry for all packers desiring the service.51 This inspection was not mandated,
but was provided when the shrimp packers applied for it, at the discretion of the Secretary of Agriculture.52
A therapeutic disaster in 1937 provided the force that led to the passage of a bill that had been in congress for
ﬁve years.53 In 1937, a new sulfa wonder drug called Elixir Sulfanilamide was marketed by a Tennessee drug
company, the S. E. Massengill Company.54 “The solvent in this untested product was a highly toxic chem-
ical analogue of antifreeze that killed over 100 people, many of whom were children.”55 This event caused
the FDA’s division of pharmacology to conduct research that developed a “statistically based method for
46Id. at 252.
47Id.
48Id. at 253.
49Id. at 255.
50Id. at 254. 21 U.S.C. § 347 (2003) of the FDCA regulates intrastate sales of colored oleomargarine or colored margarine.
51See id. at 277, for a brief discussion of the events leading to the passing of the Shrimp Amendment. See also The Shrimp
Amendment, 48 Stat. 1204 (1934) (codiﬁed as, Pub. L. No. 59-384, § 10A, 34 Stat. 768 (1906)).
52See The Shrimp Amendment, 48 Stat. 1204 (1934) (codiﬁed as, Pub. L. No. 59-384, § 10A, 34 Stat. 768 (1906)).
53Swann, supra note 2.
54James Harvey Young,, Sulfanilamide and Diethylene Glycol, in Chemistry and Modern Society: Historical Essays in
honor of Aaron J. Ihde, John Parascandola and James C. Whorton, eds., 105-25, 105 (Washington, D.C.: American
Chemical Society, 1983).
55Swann, supra note 2.
7determining the comparative toxicity of compounds.”56 It was also in the wake of this event that congress
passed the Food Drug and Cosmetic Act (FDCA), which was signed on June 25, 1938.57 Once again, this is
a demonstration of Congress’ passing of a law safeguarding public health only after a therapeutic disaster.58
ENFORCEMENT POWERS OF THE 1938 FOOD DRUG AND COSMETIC ACT
The FDCA provides the FDA with signiﬁcant enforcement powers and tools for the enforcement of the act.59
The Act for the ﬁrst time in §302 (a) gave U.S. district courts jurisdiction to issue injunctions and restrain-
ing orders for the violations of its provisions.60 The Act provides the authority to bring legal proceedings
to prosecute violations of the provisions listed in §301.61 Such violations constitute misdemeanors.62 The
ﬁnes provided for in the FDCA are much more signiﬁcant than those that had been provided in the 1906
Act.63 Section 303 (b) further provides that violations committed with an intent to defraud or mislead,
are punishable by imprisonment for not more than three years, or a ﬁne of not more than $10,000, or both.
Whereas fraud was not a prerequisite for assessing penalties on violators, where fraud could be proved, higher
penalties would be applied.
The FDCA in §304 (a) provides for the seizure of any food, drug, device or cosmetic in interstate commerce
that is adulterated or misbranded. Seized goods are proceeded against on libel of information and condemned
in any district court of the U.S. within the jurisdiction where the article was found. In addition, upon entry
56Young, Sulfanilamide and Diethylene Glycol, supra note 54 at 105.
57Swann, supra note 2.
58Swann, supra note 2.
59Federal food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codiﬁed as amended at 21 U.S.C. §
301-399 (2003)).
60See Pub. L. No. 75-717, § 301, 52 Stat. 1040 (1938) (codiﬁed as amended 21 U.S.C. § 331(2003)), for a listing of the
FDCA’s prohibited acts.
61Pub. L. No. 75-717, § 303, 52 Stat. 1040 (1938) (codiﬁed as amended 21 U.S.C. § 333 (2003)).
62Id.
63Id. at § 303(a), provided that violators would be subject to imprisonment for not more than one year, or a ﬁne of not more
than $1,000, or both. Subsequent violations would subject violators to imprisonment for not more than three years, or a ﬁne
of not more than $10,000, or both. While, Pub. L. No. 59-384, § 1, 34 Stat. 768(1906), provided for a ﬁne of not more than
$500 or one year imprisonment or both for the manufacture of adulterated food and drugs, while section 2 provided a ﬁne of
not more than $200 for the ﬁrst oﬀense and a ﬁne of not more than $300 or one year imprisonment or both, for subsequent
violations of interstate commerce of adulterated goods.
8of a decree of condemnation against the seized goods, §304 (e) provides that court costs and fees, and storage
and other expenses, are to be awarded against the claimant of the goods. In the case of minor violations,
the FDA can use its discretion to issue a written notice or
warning, rather than reporting violations for prosecution.64 Most importantly, §401 gave the FDA the au-
thority to promulgate regulations ﬁxing and establishing legal standards for food. This includes establishing
“reasonable deﬁnitions and standards of identity, reasonable standards of quality and reasonable standards
of ﬁll of containers.” Section 404 (a) gives the FDA emergency permit control authority. This applies if the
FDA ﬁnds that any class of food in interstate commerce has been contaminated with micro-organisms during
its manufacture, processing, or packing and that such contamination cannot be adequately determined after
the articles have entered interstate commerce. In this situation, the FDA is required to promulgate regula-
tions providing for the issuance of permits to the manufacturers, processors, or packers of that class of food
in the aﬀected locality. The permit would set forth conditions governing the manufacture, processing, or
packing of that class of food, for a temporary period of time, as may be necessary to protect the public health.
During this time, only permit-holders can manufacture, process or pack this class of food for introduction
into interstate commerce. The FDA is authorized under §404 (b), to suspend immediately upon notice any
permit if it is found that any of the conditions of the permit have been violated. The permit can only be
reinstated after a hearing and an inspection of the establishment, to assure that adequate measures have
been taken to comply with and maintain the conditions of the permit. During this period, permit-holders
are required under §404 (c) to provide FDA oﬃcers access to any factory for the purpose of ascertaining
whether or not the conditions of the permit are being complied with. Denial of access for such an inspection
is a ground for suspension of the permit, until such access is freely given by the operator.
In situations where a poisonous or deleterious substance is required in the production of a food, or cannot
64Pub. L. No. 75-717, § 306, 52 Stat. 1040 (1938) (codiﬁed as amended 21 U.S.C. § 336 (2003)).
9be avoided by good manufacturing practice, §406 (a) gives the FDA authority to promulgate regulations
limiting the quantity of such poison on or in the food to the extent necessary for the protection of the public.
A food with any amount of the poison below the tolerance established by the FDA is to be deemed safe,
but any quantity of the poison exceeding such tolerance is to be deemed unsafe.65 The FDA was also given
the authority to list harmless coal-tar colors suitable for use in food, drugs and cosmetics and also for the
certiﬁcation of batches of such colors.66 Section 706 provides that the admitting to listing and certiﬁcation
of coal-tar colors, shall be performed only upon payment of fees that shall be speciﬁed in regulations pro-
mulgated by the FDA.
A very important improvement in the FDCA was the elimination of the requirement to prove fraud in the
prosecution of manufacturers that made false claims for drugs.67 It now became easier for the FDA to go
after manufacturers that made false therapeutic claims for drugs. For the purposes of prosecution under
misbranding, not only did the drug labels have to list the ingredients, under §502 (f), they now had to
include adequate directions for use and warnings against use under certain conditions or by children where it
would be dangerous. Even more signiﬁcant was the provision requiring FDA approval of new drugs for safety
before they are introduced into interstate commerce.68 Pre-market approval protected consumers more by
preventing violations, rather than merely prosecuting violations after the injuries had occurred.69 Under
§505 (e), the FDA was also given the authority to suspend applications for new drugs already approved when
clinical experience and tests by new methods showed the drug to be unsafe, or when the application was
later found to contain any untrue statement of a material fact. This is a very important enforcement power,
because it allows the FDA to revisit approved applications for new drugs after new technological advances
65Id. at § 406(a) (codiﬁed as amended 21 U.S.C. § 346 (2003)).
66For this provision with respect to food, see id. at § 406(b), 52 Stat. 1040 (1938) (repealed 1960), for drugs, see id. at §
504 (repealed 1960), and for cosmetics, see id. at § 604 (repealed 1960).
67Id. at 502(a) (codiﬁed as amended 21 U.S.C. § 352(a) (2003)), simply provided that a drug or device shall be deemed to
be misbranded if its labeling is false or misleading in any particular.
68See id. at §505 (codiﬁed as amended 21 U.S.C. § 355 (2003)).
69Wallace F. Janssen, The Story Of The Laws Behind The labels: Part II, 1938 – The FDCA,
http://vm.cfsan.fda.gov/∼lrd/history1a.html.
10show the approved drugs to be unsafe.
Other general powers are given to the FDA for the purposes of enforcement of the FDCA. Section 702 (c)
gives the FDA authority to inspect the records of any department or independent establishment in the exec-
utive branch of the Government. Also, under §703, carriers engaged in interstate commerce are required to
permit FDA oﬃcers to have access to and to copy all records showing the movement in interstate commerce
of any food, drugs and cosmetics. Failure to permit such access is unlawful.70 This enables the FDA to be
aware when these articles are in interstate commerce and to examine them for compliance.
More importantly, FDA oﬃcers are authorized under §704, upon request and consent, to inspect factories,
warehouses and establishments in which food, drugs, devices, or cosmetics are manufactured, processed,
packed, or held, for introduction into interstate commerce, or held after such introduction. They are also
authorized to inspect any vehicle being used to transport or hold such articles in interstate commerce. The
FDA is authorized under §705 (b) to disseminate information regarding food, drugs, devices, or cosmetics
in situations involving, in the opinion of the FDA, imminent danger to health or gross deception of the
consumer. Publicity is a very important and eﬀective enforcement tool.71 The FDA is also authorized under
§801 (a), to examine samples of food, drugs, devices, and cosmetics which are being imported or oﬀered for
import into the U.S. If such samples are found to be adulterated, misbranded, or forbidden or restricted in
sale in the country in which it was produced or from which it was exported, then the FDA is authorized to
refuse such article admission. Furthermore, §801 (c) provides that all charges for storage and labor on any
article which has been refused admission, shall be paid by the owner or consignee.
The FDCA and the FDA’s regulations do not authorize the FDA to order a recall.72 The FDA however has
70Pub. L. No. 75-717, § 703, 52 Stat. 1040 (1938) (codiﬁed as amended at 21 U.S.C. § 373 (2003)).
71See, Richard S. Morey, FDA Publicity Against Consumer Products – Time for Statutory Revitalization? 30 Business
Lawyer 165 (November 1974) (discussing FDA’s use of publicity and concluding that the FDA exceeds its statutory bound in
exercising its publicity powers).
72John M. Packman, Civil and Criminal Liability Associated With Food Recalls 53 Food Drug L. J. 437 (1998).
11regulations that set forth its recall policy should a manufacturer decide to recall a product.73 “These recall
regulations are guidelines only and do not have the force of law.”74 If a company refuses to voluntarily recall
a violative product, there are no penalties provided by the FDCA or the FDA regulations.75 However, that
company’s liability would arise from the product’s violations.76 The company’s liability from possible class
actions and punitive damages can be increased signiﬁcantly by a refusal to recall a violative product.77
Many of the problems of the 1906 Act were solved by the FDCA. The FDA could not only bring legal pro-
ceedings with higher penalties, it could seek injunctions, seize violative goods, establish legal standards for
food, establish tolerance levels for poisons in food, exercise emergency permit control authority, pre-approve
new drugs, suspend pre-approved drugs, inspect factories, refuse admission to violative imported goods, list
approved coal-tar colors and certify each batch of such colors for use in food, drugs and cosmetics. Even
with this signiﬁcant expansion of the FDA’s enforcement powers there was still room for improvement.
FURTHER EXPANSION OF FDA ENFORCEMENT POWERS BY THE AMENDMENTS TO THE FDCA
Congress later passed amendments to the FDCA further expanding FDA’s enforcement powers. Congress
provided for the certiﬁcation of batches of drugs composed wholly or partly of insulin,78 penicillin,79 strep-
73See 21 C.F.R. §§ 7.40 - 7.59 (1997)
74Packman, supra note 72, at 439 n.1.
75Id. at 439
76Id.
77Id.
78Act of December 22, 1941, Pub. L. No. 77-366, ch. 613, 55 Stat. 851 (1941) (amending Pub. L. No. 75-717, 52 Stat 1040
(1938)) (repealed 1997).
79Act of July 6, 1945, Pub. L. No. 79-139, ch. 281, 59 Stat. 463 (1945) (amending Pub. L. No. 75-717, 52 Stat 1040 (1938))
(repealed 1997).
12tomycin,80 chlortetracydine,81 chloramphenicol82 and bacitracin.83 The FDCA prohibited poisonous sub-
stances in food but required no showing that food ingredients were safe. The FDA could therefore put an end
to the use of poisons it knew of, but did not have adequate resources to carry out research needed to assure
that all food chemicals were safe.84 The problem of chemicals in food produced three amendments: the
Pesticide Amendment (1954), the Food Additives Amendment (1958), and the Color Additive Amendments
(1960).85
The Pesticide Amendment of 1954 gave the FDA the authority to promulgate regulations establishing toler-
ances for pesticide chemicals in or on raw agricultural commodities.86 This law provided that persons that
had registered, or had submitted an application for the registration of an economic poison under the Federal
Insecticide, Fungicide and Rodenticide Act, could petition the FDA to promulgate regulations establishing
a tolerance for a pesticide chemical that was a constituent of such economic poison.87 The FDA was further
authorized to charge fees to persons petitioning for the promulgation of regulations setting tolerances for
diﬀerent pesticide chemicals.88
The Food Additives Amendment of 1958 requires FDA approval of food additives for safety.89 This law
provides that any person intending to use a food additive has to ﬁle a petition with the FDA, proposing the
80Act of March 10, 1947, Pub. L. No. 80-16, ch. 16, 61 Stat. 11 (1947) (amending Pub. L. No. 75-717, 52 Stat 1040 (1938))
(repealed 1997).
81Act of August 5, 1953, Pub. L. No. 83-201, ch. 334, 67 Stat. 389 (1953) (amending Pub. L. No. 75-717, 52 Stat 1040
(1938)) (repealed 1997).
82Ac of July 13, 1949, Pub. L. No. 81-164, ch. 305, 63 Stat. 409 (1949) (amending Pub. L. No. 75-717, 52 Stat 1040 (1938))
(repealed 1997).
83Id.
84Janssen, supra note 69.
85Id.
86The Pesticide Amendment of 1954, Pub. L. No. 83-518, ch. 559, 68 Stat. 511 (1958) (amending Pub. L. No. 75-717, 52
Stat 1040 (1938)) (codiﬁed as amended 21 U.S.C. § 346a (2003)).
87Id. at § 3, adding § 408(d) (codiﬁed as amended 21 U.S.C. § 346a (2003)).
88Id. at § 3, adding § 408 (o). (codiﬁed as amended 21 U.S.C. § 346a (2003)) See also the Food Quality Protection Act of
1996, Pub. L. No. 104-170, 110 Stat. 1489 (1996) (amending 21 U.S.C. § 346a (2003)), for the procedure and conditions for
establishing, modifying, and revoking tolerances and exemptions for pesticide chemical residues.
89The Food Additives Amendment of 1958, Pub. L. 85-929, 72 Stat. 1784, (1958) (amending Pub. L. No. 75-717, 52 Stat
1040 (1938)) (codiﬁed as amended at 21 U.S.C. § 348 (2003)).
13issuance of a regulation prescribing the conditions under which such additive may be safely used.90 This
amendment gives the FDA the authority to ﬁx tolerances where a tolerance limitation is required to assure
that the proposed use of an additive will be safe.91 The amendment however denies the FDA authority
to issue tolerance regulations where the food additive in found to induce cancer when ingested by man or
animal.92
The Color Additive Amendments of 1960 require FDA approval of color additives for safety.93 The FDA
is authorized to list through regulation, color additives for use in food, drugs and cosmetics separately, if
such additives are safe for such use.94 The FDA is further authorized to provide for the certiﬁcation of
batches of color additives so listed, for compliance with the requirement for such additives established by
regulation.95 This amendment, like the Food Additives Amendment, has an anticancer clause, which denies
the FDA authority to list for any use, a color additive which is found to induce cancer when ingested by
man or animal.96 “With these laws on the books, it could be said for the ﬁrst time that no substance can
legally be introduced into the U.S. food supply unless there’s been a prior determination that it is safe.”97
The problem of inadequate resources for research to assure that all food chemicals were safe was solved by
requiring the manufacturers to do the research.98
90Id. at § 4, adding § 409 (b)(1) (codiﬁed at 21 U.S.C. § 348(b)(1) (2003)).
91See Pub. L. No. 75-717, § 409(c)(4), 52 Stat 1040 (1938) (codiﬁed as amended 21 U.S.C. § 348(c)(1)(A) (2003)).
92See Pub. L. No. 75-717, § 409(c)(3)(A), 52 Stat 1040 (1938) (codiﬁed at 21 U.S.C. § 348(c)(3)(A) (2003)), which provides
“that no additive shall be deemed to be safe if it found to induce cancer when ingested by man or animal, or if it is found, after
tests which are appropriate for the evaluation of the safety of food additives, to induce cancer in man or animal.”
93The Color Additive Amendments of 1960, Pub. L. No. 86-618, 74 Stat. 397 (amending Pub. L. No. 75-717, 52 Stat 1040
(1938)) (codiﬁed as amended at 21 U.S.C. § 379e (2003)).
94Id. at § 103(b), amending § 706 (b)(1) (codiﬁed at 21 U.S.C. § 379e(b)(1) (2003)).
95Id. at § 103(b), amending § 706 (c) (codiﬁed at 21 U.S.C. § 379e(c) (2003)).
96See id. at § 103(b), amending § 706 (b)(5)(B) (codiﬁed at 21 U.S.C. § 379e(b)(5)(B) (2003)), which provides “that a color
additive shall be deemed unsafe...if the additive is found by the FDA to induce cancer when ingested by man or animal, or if
it is found by the FDA, after tests which are appropriate for the evaluation of the safety of additives for use in food, to induce
cancer in man or animal.”
97Janssen, supra note 69.
98Id.
14There was another therapeutic disaster in Europe between 1961 and 1962. Thousands of infants were born
deformed to mothers who had taken thalidomide, a new sedative.99 Although thalidomide had never been
approved in the U.S., these incidents drove Congress to enhance legislation that was pending in Congress
and to pass the Drug Amendments of 1962.100 The 1962 Drug Amendments further strengthened the FDCA
by increasing control over prescription drugs, new drugs, and investigational drugs.101 The law required
all new drugs to be approved by the FDA before being introduced into interstate commerce.102 It requires
eﬀectiveness as well as safety before a drug could be approved for marketing.103 It transferred the regulation
of prescription drug advertising from the Federal Trade Commission (FTC) to the FDA and requires drug
advertisements to contain a brief summary relating to side eﬀects, contraindications and eﬀectiveness.104
The Act required drug manufacturers to conform to good manufacturing practices for the drug industry,105
and required drug companies to establish and maintain records of data relating to clinical experience with
respect to their drugs and report such data to the FDA.106 It also granted the FDA greater powers to access
company records.107 It required certiﬁcation of all antibiotics by the FDA before they could be marketed.108
The Act authorized the FDA to carry out inspections of factories, warehouses and consulting laboratories
where prescription drugs are manufactured, processed, packed or held. The inspection authorized extended
to all things in the establishments being inspected, as well as records, ﬁles papers processes, controls and
facilities.109
99Janssen, supra note 5, at 137.
100Wallace F. Janssen, The Story Of The Laws Behind The labels, Part III, 1962 Drug Amendments,
http://vm.cfsan.fda.gov/∼lrd/histor1b.html.
101Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962) (amending Pub. L. No. 75-717, 52 Stat 1040 (1938))
(codiﬁed principally at 21 U.S.C. §§ 351, 352, 355, 374 (2003)).
102Id. at § 104(a) (codiﬁed at 21 U.S.C. § 355(a) (2003)).
103Id. at § 102(a) & (b) (codiﬁed at 21 U.S.C. §§ 321(p), 355(b) (2003)).
104Id. at § 131(a) (codiﬁed at 21 U.S.C. § 352(n) (2003)).
105Id. at § 101 (codiﬁed at 21 U.S.C. § 351(a) (2003)).
106Id. at § 103(a) (codiﬁed at 21 U.S.C. § 355(k)(1) (2003)).
107Id. (codiﬁed at 21 U.S.C. § 355(k)(2) (2003)).
108Id. at § 105 (repealed 1997).
109See id. at § 201(a) (codiﬁed at 21 U.S.C. § 374(a) (2003)), this inspection does not however extend to “ﬁnancial data, sales
data (other than shipment data), pricing data, personnel data (other than data as to qualiﬁcations of technical and professional
personnel performing functions subject to this Act), and research data (other than data relating to new drugs subject to
15Since 1962, “thousands of prescription drugs have been taken oﬀ the U.S. market because they lacked ev-
idence of safety and or eﬀectiveness, or they have had their labels changed to reﬂect the known medical
facts.”110 The requirement of monitoring new drugs for eﬃcacy as well as safety has been criticized for de-
laying the introduction of new drugs into the market. Economist Sam Peltzman of the University of Chicago
conducted a study that concluded that the 1962 amendments had signiﬁcantly reduced the introduction of
eﬀective new drugs from an average of 41.5 annually from 1951-1962, to just 16.1 annually from 1963-1970.111
Peltzman blames increased clinical testing requirements and more stringent eﬃcacy standards of the 1962
Drug amendments for this “decline in drug innovation.”112 Other studies have found that the average cost
of developing a new drug from discovery to approval has risen from $138 million in the 1970s, to $802 million
in the 1990s.113 The FDA was under pressure particularly from AIDS activists, to allow higher levels of risk
for new drugs that were intended to treat individuals who were terminally ill, in order to facilitate faster
approval of those drugs.114
In response to the criticism of “drug lag,” the FDA introduced ““fast-track” approval of the AIDS drug AZT,
which was cleared for use within two years after it was discovered to be eﬀective against the HIV virus.”115
AZT was approved despite its deadliness and the serious side eﬀects observed during clinical trials.116 Since
the Prescription Drug User Fee Act was passed in 1992, the average combined clinical and approval times for
new drugs has dropped by 25% (from 9.2 years to 6.9 years).117 Recently, the FDA “launched an initiative
reporting and inspection).
110Janssen, supra note 100.
111See Sam Peltzman, An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments, Journal of Polit-
ical Economy, 1049-91, 1053 (Sept - Oct. 1973).
112Id. at 1089.
113See the Tufts Center for the Study of Drug Development 2002 Outlook Report, 2,
http://csdd.tufts.edu/InfoServices/OutlookPDFs/Outlook2002.pdf. (assessing major drug development issues for
the year 2002).
114See Daniel Henninger, Drug Lag, in The Concise Encyclopedia of Economics, The Library of Economics and Liberty,
http://www.econlib.org/library/Enc/DrugLag.html, for the various tactics used by AIDS activists to ﬁnally get the FDA to
introduce the “fast track” approach of approving AIDS drugs.
115Id.
116Id.
117See the Tufts Center for the Study of Drug Development 2003 Outlook Report, 1,
http://csdd.tufts.edu/InfoServices/OutlookPDFs/Outlook2003.pdf. (assessing major drug development issues for
16to further improve the development and availability of innovative medical products.”118 The initiative is
geared towards “making innovative medical technologies available sooner and reducing the costs of devel-
oping safe and eﬀective medical products, while maintaining FDA’s traditional high standards of consumer
protection.”119
Around 1960, there was publicity involving the abuse of depressant and stimulant drugs in the U.S. An oﬃcial
report stated that 852,000 pounds of barbiturates had been produced in 1960. This meant that there were
thirty-three one-grain capsules for each person in the U.S.120 In 1961, there were claims that tranquilizers
were competing with barbiturates as suicide drugs.121 It was revealed and publicized, that the pilot of a
plane that had crashed had been taking tranquilizers, and that benzedrine was probably involved in causing
a multiple-car accident on the New Jersey Turnpike.122 The sentiment was that there was widespread abuse
of barbiturates and other sedatives, stimulants, and tranquilizers. In January 1965, President Johnson urged
Congress to expedite legislation to bring the production and distribution of barbiturates, amphetamines,
and other psychotic drugs under more eﬀective control.123 A bill addressing this issue had already been
introduced in the legislature and resulted in the Drug Abuse Control Amendments of 1965. These amend-
ments were passed to “establish special controls for depressant, stimulant and counterfeit drugs.”124 They
authorized the FDA to promulgate regulations designating any drug that it found to have a potential for
abuse because of its depressant, stimulant or hallucinogenic eﬀect, as a “depressant or stimulant drug.”125
the year 2003).
118See the Press release, FDA Launches Initiative to Improve the Development and Availability of Innovative Medical Products,
(January 31, 2003), http://www.fda.gov/bbs/topics/NEWS/2003/NEW00867.html.
119Id. See also, Improving Innovation in Medical Technology: Beyond 2002 (January 31, 2003),
http://www.fda.gov/bbs/topics/news/2003/beyond2002/report.html, for a report containing an outline of FDA’s pro-
posed actions.
120Rufus King, The Drug Hang Up, America’s Fifty-Year Folly, ch, 26, Drug Abuse Control, 1965. Schaffer Library of
Drug Policy. http://www.druglibrary.org/special/king/dhu/dhu26.htm.
121Id.
122Id.
123Id.
124Drug Abuse Control Amendments of 1965, Pub. L. No. 89-74, 79 Stat. 226-235 (1965) (amending Pub. L. No. 75-717, 52
Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 331(i), 351-360 (2003)).
125Id. at § 3(a).
17Such drugs can only be manufactured or processed by speciﬁed persons,126 who have to register,127 keep
records,128 and are subject to FDA inspection.129 An FDA Bureau of Drug Abuse Control was formed in
1965. This bureau conducted undercover drug investigations and enabled the prosecution and “conviction
of hundreds of racketeers and pushers.”130 In 1968, this bureau was transferred to the Federal Bureau of
Narcotics in the Department of Justice.131 Congress also found that there had been signiﬁcant traﬃc in
counterfeit drugs that posed a considerable risk to the public health.132 Congress recognized that while such
drugs were considered misbranded under the FDCA, it was diﬃcult to determine “the place for interstate
origin of such drugs and, if that place is discovered, the fact that the implements for counterfeiting are not
subject to seizure” meant that there was a need for more eﬀective controls of these drugs regardless of their
interstate or intrastate origins.133 This law makes it a crime to make, sell, possess or conceal any punch,
die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other
identifying mark, on any drug or container or labeling thereof, so as to cause such drug to be a counterfeit
drug.134 This therefore means that counterfeit drugs can be seized for misbranding and possession of instru-
ments used to counterfeit can be proceeded against as a prohibited act.
Prior to 1968, there was a very ineﬃcient and cumbersome system for the regulation of animal drugs. Animal
drugs were governed by one of or a combination of the new drug law, the antibiotic law and the food additive
law.135 This involved “three separate statutory provisions; three separate administrative procedures and;
three separate parts of the [FDA]”136 The Animal Drug Amendments of 1968 combined these three regula-
126Id. at § 3(b), adding § 511(a) (repealed 1970).
127Id. at § 4 (b), adding § 510(b) (repealed 1970).
128Id. at § 3(b), adding § 511(d)(1) (repealed 1970).
129Id. at § 3(b), adding § 511(d)(2)(A) (repealed 1970).
130Janssen, supra note 100.
131Id.
132Pub. L. No. 89-74, § 9(a), 79 Stat. 226-235 (1965).
133Id.
134Id. at § 9(c)(2).
135Eugene I. Lambert, The Reformation of Animal Drug Law: The Impact of 1996, Food and Drug Law Journal, vol. 52,
277 (1997), http://www.fdli.org/pubs/Journal%20Online/52 3/3art.pdf.
136Id.
18tory systems into a uniﬁed process for the approval of animal drugs.137 The FDA established the Bureau
of Veterinary Medicine, today, the Center for Veterinary Medicine, to carry out animal drug approval. This
center however only received “full authority over both human and animal aspects of animal drug approvals”
in 1983.138 The Animal Drug Amendments of 1968 were passed to assure the safety and eﬀectiveness of new
animal drugs.139 The amendments mandate FDA approval of new animal drugs and animal feed containing
a new animal drug, before they can be introduced into interstate commerce.140 They also authorize the
FDA to suspend approved applications if the drug presents an “imminent hazard”141 or withdraw approved
applications if the applicant fails to maintain required records142 or make required reports to the FDA.143
The FDA is also authorized to certify “batches of new animal drugs composed wholly or partly of any kind
of penicillin, streptomycin, chlortetracycline, chloramphenicol, or bacitracin or any derivative thereof.”144
In order to facilitate more eﬀective regulation of drugs, the FDA created two voluntary programs in an eﬀort
to compile a “comprehensive drug inventory for drug listings.”145 Following the failure to accomplish this
task through the voluntary programs, the FDA passed regulations pursuant to the Drug Listing Act of 1972,
to make drug listing mandatory.146 The Act authorizes the FDA to require all registered drug manufacturers
to submit a list of all the drugs they manufacture and market.147 In addition, it requires them to report
twice a year in June and December, a list of all drugs introduced by the registrant since the last list ﬁled,
137Id.
138Id. at 277 n.11.
139The Animal Drug Amendments of 1968, Pub. L. No. 90-399, 82 Stat. 342 (1968) (amending Pub. L. No. 75-717, 52 Stat
1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 351-360 (2003)).
140Id. at § 101(b), adding § 512(a) (codiﬁed at 21 U.S.C. § 360b(a) (2003)).
141Id. at § 101(b), adding § 512(e)(1)(E) (codiﬁed at 21 U.S.C. § 360b(e)(1)(E) (2003)).
142See id. at § 101(b), adding § 512(l) (codiﬁed at 21 U.S.C. § 360b(l) (2003)), for record-keeping requirements for new animal
drugs and Section 512(m)(5) for record-keeping requirements for animal feed containing a new animal drug.
143See id. at § 101(b), adding § 512 (e)(2)(A) (codiﬁed at 21 U.S.C. § 360b(e)(2)(A) (2003)), for more reasons why the FDA
may withdraw approved applications, see Section 512 (e).
144Id. at § 101 (b), adding § 512 (n)(1) (repealed 1988).
145See Drug Registration and Listing System, http://www.fda.gov/cder/handbook/druglist.htm.
146The Drug Listing Act of 1972, Pub. L. No. 92-387, 86 Stat. 560-562 (1972) (amending Pub. L. No. 75-717, 52 Stat 1040
(1938)) (codiﬁed at 21 U.S.C. § 360(j) (2003)).
147Id. at § 3, adding § 510(j)(1) (codiﬁed at 21 U.S.C. § 360(j)(1)).
19give a notice of discontinuance of a drug and of resumption of a previously discontinued drug.148
Title V of the Health Research and Health Services Amendments of 1976 authorizes the FDA, through a
U.S. attorney, to bring suit against the manufacturer of a food that is misbranded due to its advertising, if
the FTC declines to bring such action.149 In addition to the FDA’s enforcement power with respect to false
and misleading advertising of drugs,150 it can now proceed against false and misleading advertising of food.
Technological advances had increased the number and complexity of medical devices. These advances im-
proved medical care signiﬁcantly.151 However, there were also many complications involving medical devices:
“mechanical failure, faulty design, poor manufacturing quality, adverse eﬀects of materials implanted in the
body, improper maintenance/speciﬁcations, user error, compromised sterility/shelf life and electromagnetic
interference among devices.”152 The Cooper Commission reported in 1970 that medical devices had caused,
or were involved in more than 700 deaths and 10,000 injuries.153 Congress, then passed the Medical Device
Amendments of 1976 further increasing FDA’s enforcement authority with respect to medical devices, and
to ensure the safety and eﬀectiveness of medical devices intended for human use.154 The law authorizes the
FDA to classify medical devices into three categories:155 class I devices subject only to general controls;156
class II devices subject to performance standards and;157 class III devices subject to premarket approval.158
The FDA is authorized to prescribe regulations setting forth the basis for determining and authorizing the
148Id. at § 3, adding § 510(j)(2) (codiﬁed at 21 U.S.C. § 360(j)(2)).
149Act of April 22, 1976, Pub. L. No. 94-278, Title V, § 707, 90 Stat 412 (1976) (codiﬁed at 21 U.S.C § 378 (2003)).
150See supra note 101.
151Statement by Michael Friedman, M.D., Lead Deputy Commissioner of the FDA, before the U.S. House
of Representatives Subcommittee on Health and the Environment Committee on Commerce (April 30, 1997),
http://www.fda.gov/ola/1997/devices.htm.
152Id.
153Id.
154The Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539-583 (1976) (amending Pub. L. No. 75-717, 52
Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 360c - 360k (2003)).
155Id. at § 2, adding § 513 (b)(1) (codiﬁed as amended 21 U.S.C § 360c(b)(1) (2003)). See the rest of § 513(b) for the process
the FDA has to follow in classifying and reclassifying medical devices.
156See id. at § 2, adding § 513 (a)(1)(A) (codiﬁed as amended 21 U.S.C § 360c(a)(1)(A) (2003)), for the conditions necessary
for a drug to be classiﬁed under class I
157See id. at § 2, adding § 513(a)(1)(B) (codiﬁed as amended 21 U.S.C § 360c(a)(1)(B) (2003)), for the conditions necessary
to for a drug to be classiﬁed under class II.
158See id. at § 2, adding § 513(a)(1)(C) (codiﬁed as amended 21 U.S.C § 360c(a)(1)(B) (2003)), for the conditions necessary
to for a drug to be classiﬁed under class III.
20eﬀectiveness of a medical device.159 It is authorized to promulgate regulations establishing performance
standards for class II devices,160 and can also amend or revoke them.161 The amendments also authorize the
FDA to prescribe regulations requiring premarket approval of class III devices,162 and to withdraw approval
of applications already given where certain conditions are present.163
In keeping with the FDA’s mission to safeguard the public health, the Medical Device Amendments of 1976
also authorize the FDA to promulgate regulations banning a device if it “presents substantial deception or
an unreasonable and substantial risk of illness or injury.”164 In addition, the FDA is authorized to prescribe
regulations conditioning the sale, distribution and use of a medical device upon authorization of a licensed
practitioner if it determines that “there cannot otherwise be reasonable assurance of its safety and eﬀective-
ness.”165 The amendments also require manufacturers of medical devices to register166 with the FDA, to
establish and maintain records and make reports that the FDA may require of them through regulations.167
They authorize the FDA to inspect facilities where medical devices are manufactured,168 and give it access
to records that it requires them to keep.169 The FDA is also authorized to promulgate regulations setting
forth good manufacturing practice for the medical device industry, to assure the safety, eﬀectiveness and
compliance of the devices with the FDCA as amended.170 To ensure the eﬀectiveness of FDA’s regulation
of medical devices, the amendments provide that FDA regulations preempt any state regulation of medical
159Id. at § 2, adding § 513(a)(2) (codiﬁed as amended 21 U.S.C § 360c(a)(2) (2003)).
160Id. at § 2, adding § 514(a)(1) (codiﬁed as amended 21 U.S.C § 360d(a)(1) (2003)). See also § 514 for the rules setting forth
the procedure for setting performance standards.
161Id. at § 2, adding § 514(g)(4)(A) (codiﬁed as amended 21 U.S.C § 360d(b)(4)(A) (2003)).
162Id.at § 2, adding § 515(b)(1)(B) (codiﬁed as amended 21 U.S.C. § 360e(b)(1)(B) (2003)). See also the Section 515 for the
premarket approval requirements.
163See id. at § 2, adding § 515(e)(1) (codiﬁed as amended 21 U.S.C. § 360e(e)(1) (2003)), for the conditions that if present,
allow the FDA to withdraw approval of an application.
164Id. at § 2, adding § 516(a) (codiﬁed at 21 U.S.C. § 360f(a) (2003)).
165See id. at § 2, adding § 520(e) (codiﬁed as amended 21 U.S.C. § 360j(e) (2003)), such devices are referred to as “restricted
devices.”
166Id. at § 4(a), Section 510 (codiﬁed as amended 21 U.S.C. § 360 (2003)).
167Id. at § 2, adding § 519(a) (codiﬁed as amended 21 U.S.C. § 360i(a) (2003)).
168Id. at § 6(a), § 704 (a) (codiﬁed as amended 21U.S.C. § 374(a) (2003)).
169Id. at § 6(e) (codiﬁed as amended 21U.S.C. § 374(e) (2003)).
170Id. at § 2, § 520(f)(1)(A) (codiﬁed at 21 U.S.C. § 360j(f)(1)(A) (2003)).
21devices.171 The Act gives the FDA the authority to make exemptions from this provision if a state require-
ment is more stringent than an FDA requirement and is required by compelling local conditions.172
The Safe Medical Devices Act of 1990 was passed further improve the regulation of medical devices.173 This
Act requires “device user facilities” to report to the FDA if they reasonably believe that a device caused or
contributed to the death, serious illness or injury of a patient of the facility.174 The Act further requires
registered manufacturers of medical devices that are permanently implantable, or life sustaining (and any
others that the FDA may designate), to adopt a method of “device tracking” to trace these devices to the
user level, and to conduct “postmarket surveillance” to monitor products that have been introduced into
commerce.175 This Act changed class II devices from being subject to performance standards, to being
subject to “special controls,” which include performance standards.176 Most importantly this Act gives the
FDA the authority to issue orders requiring immediate cessation of distribution and use of a device that it
ﬁnds would “cause serious adverse health consequences or death.” Further, if after an informal hearing the
FDA ﬁnds that adequate grounds exist to support the order, it can amend the order to require a recall of
the device.177 The Act also authorized the FDA to exempt “devices designed to treat or diagnose a disease
or condition that aﬀects fewer than 4,000 individuals in the U.S.,” from the eﬀectiveness requirements of the
FDCA as amended.178
There was another crisis in 1978 when one of the big infant formula manufacturers stopped adding salt to
171Id. at § 2, § 521(a) (codiﬁed at 21 U.S.C. § 360k(a) (2003)).
172Id. at § 2, § 521(b) (codiﬁed at 21 U.S.C. § 360k(b) (2003)).
173The Safe Medical Devices Act of 1990, Pub. L. No. 101-629, 104 Stat. 4511-4529 (1990) (amending Pub. L. No. 75-717,
52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 360c – 360l (2003)).
174Id. at § 2(a), adding § 519(b)(1) (codiﬁed as amended 21 U.S.C. § 360i(b)(1) (2003)).
175See id. at § 3(b)(1), adding § 519(e) (codiﬁed as amended 21 U.S.C. § 360i(e) (2003)), for “device tracking” requirements,
and id. at § 10, adding § 522, (codiﬁed as amended 21 U.S.C § 360l (2003)), for “postmarket surveillance requirements.
176Id. at § 5(a)(2) (codiﬁed as amended 21 U.S.C § 360c(a)(1)(B) (2003)), special controls also include “postmarket surveillance,
patient registries, development and dissemination of guidelines...and other appropriate actions” deemed necessary by the FDA,
to assure safety and eﬀectiveness.
177Id. at § 8 (codiﬁed as amended 21 U.S.C § 360h(e) (2003)).
178See id. at § 14, adding § 520(m)(2) (codiﬁed as amended 21 U.S.C § 360j(m)(2) (2003)), for the conditions necessary to
obtain such a “humanitarian device exemption.”
22two of its soy products.179 These reformulated infant formula products ended up having insuﬃcient amounts
of chloride, which is an important nutrient for the growth and development of infants. “By mid-1979, a
substantial number of infants had been diagnosed with hypochloremic metabolic alkalosis, a syndrome asso-
ciated with chloride deﬁciency.”180 A connection was found between this condition and the protracted use of
the reformulated soy formula.181 Congress then passed the Infant Formula Act of 1980 to assure the safety
and nutrition of infant formulas.182 The Act lists the nutrients and amounts of which must be contained in
an infant formula.183 It authorizes the FDA to revise the list of nutrients and the required level for the nu-
trients listed in the Act.184 It also authorizes the FDA to establish quality control procedures, which include
the periodic testing of infant formulas for compliance with the Act.185 Manufacturers of infant formula are
also required to keep records of distribution of the infant formula, to facilitate recalls of the formula when
necessary.186 In the 1986 amendments to this Act, the FDA is authorized to promulgate regulations setting
forth good manufacturing practices and quality control procedures.187
In 1982, there was a tragic incident that involved the sudden deaths of seven people in Chicago that had
ingested tylenol capsules that had been laced with cyanide. The capsules had been placed in six diﬀer-
ent stores by an unknown person.188 This act was dubbed “product tampering.”189 The FDA responded
to this tragedy by issuing regulations prescribing tamper-resistant packaging requirements for all over-the-
179Food Advisory committee Meeting on Infant Formula, http://www.fda.gov/OHRMS/DOCKETS/ac/02/briefing/3852b1 01.pdf.
180Id.
181Id.
182The Infant Formula Act of 1980, Pub. L. No. 96-359, 94 Stat. 1190-1193 (1980) (amending Pub. L. No. 75-717, 52 Stat
1040 (1938)) (codiﬁed principally at 21 U.S.C. § 350a (2003)).
183See id. at § 2, adding § 412(g) (codiﬁed as amended 21 U.S.C. § 350a(i) (2003)).
184Id. at § 2, adding § 412(a)(2) (codiﬁed as amended 21 U.S.C. § 350a(i)(2) (2003)).
185Id.
186Id. at § 2, adding § 412(e) (codiﬁed as amended 21 U.S.C. § 350a(g) (2003)).
187Act of October 27, 1986, Pub. L. No. 99-570, § 4014(a)(7), adding § 412(b)((2)(B) 100 Stat 3207-116 (1986) (amending
Pub. L. No. 75-717, 52 Stat 1040 (1938)) (codiﬁed at 21 U.S.C. § 350a(b)(2)(B) (2003)), these quality control procedures
include: testing each nutrient premix to assure compliance with the certiﬁcations of such premix by a premix supplier; testing
each batch of infant formula for each required nutrient by manufacturers before distribution and ; regularly scheduled testing
for each required nutrient by manufacturers during the shelf life of the infant formula.
188The Tylenol Murders, http://www.personal.psu.edu/users/w/x/wxk116/tylenol/.
189Id.
23counter (OTC) drug products and certain cosmetic products.190 These regulations require that such product
packages provide visual evidence of package tampering and a statement informing the consumer about the
tamper-resistant feature.191 The regulations provide that OTC drug products not packaged in a tamper
resistant package that are oﬀered for retail sale will be considered adulterated under the FDCA.192 Congress
also passed the Federal Anti Tampering Act of 1983.193 While this Act is not an amendment to the FDCA,
it authorizes the FDA and the Department of Agriculture to investigate violations of its provisions.194 The
Act principally makes tampering with consumer product a crime and provides for various ﬁnes and prison
terms for: attempting to tamper and actual tampering; 195 knowingly communicating false information that
a consumer product has been tampered;196 threatening to tamper in circumstances in which a threat may
reasonably be expected to be believed, and;197 conspiring to tamper plus any conduct in furtherance of such
tampering.198 While product tamperings have decreased, there has still been a few incidents of product
tampering throughout the country.199
Before the 1980s, there were very few drugs for rare diseases, “orphan drugs.” There had not been adequate
development of drugs for such rare diseases because the cost of developing the drugs is extremely high in
relation to the sales of the drugs.200 Jack, Klugman, an actor in a hit TV medical drama, “Quincy,” is rec-
ognized as part of the driving force that increased public awareness of the orphan drug problem. Klugman
used his show to publicize this problem, at one time airing an “episode...mirroring the real-life holdup of the
190Packaging Regulations, http://www.polybottle.com/Pages/Filling/PackagingRegulations.html#TAMPER-RESISTANT%20PACKAGING%20REGULATIONS.
191See 21 CFR 211.132(a).
192See 21 CFR 211.132(a).
193The Federal Anti Tampering Act of 1983, Pub. L. No. 98-127, 97 Stat. 831 (1983) (codiﬁed at 18 U.S.C. § 1365 (2003)).
194Id. at § 2, adding § 1365(f) (codiﬁed at 18 U.S.C. § 1365(g) (2003)).
195Id. at § 2, adding § 1365(a) (codiﬁed at 18 U.S.C. § 1365(a) (2003)).
196Id. at § 2, adding § 1365 (c) (codiﬁed at 18 U.S.C. § 1365(c) (2003)).
197Id. at § 2, adding § 1365 (d) (codiﬁed at 18 U.S.C. § 1365(d) (2003)).
198Id. at § 2, adding § 1365 (e) (codiﬁed at 18 U.S.C. § 1365(e) (2003)).
199The Tylenol Murders supra note 188, later product tamperings that resulted in deaths included, “Lipton Cup-A-Soup in
1986, Exedrin in 1986, Tylenol again in 1986, Sudafed in 1991, and Goody’s Headache Powder in 1992.”
200John Henkel, How TV Launched The Orphan Drug Law, http://www.fda.gov/fdac/features/1999/399 orph.html. (John
Henkel is a staﬀ writer for FDA Consumer).
24[orphan drug] bill taking place on Capitol Hill.”201 This created widespread support that resulted in the
passage of the Orphan Drug Act of 1983.202 This Act was passed to encourage the development of orphan
drugs.203 The act amends several laws, including the internal revenue code, in order to create incentives for
the development of orphan drugs. The Act authorizes the FDA to provide recommendations upon request,
for the non-clinical and clinical investigations that have to be conducted with an orphan drug before it is
approved for the disease it is meant to treat.204 The FDA is authorized to designate a drug, upon the request
of the drug manufacturer, as a drug for a rare disease.205 The FDA is authorized by this act to “make grants
to and enter into contracts with public and private entities and individuals to assist in defraying the costs
of qualiﬁed clinical testing expenses incurred in connection with the development of drugs for rare diseases
and conditions.”206 The FDA is authorized to create technical and scientiﬁc review groups that facilitate its
enforcement of the FDCA as amended.207
Prior to 1986, the FDA had construed the FDCA to allow the export of approved drugs, but not unap-
proved new drugs.208 This construction disadvantaged the U.S. pharmaceutical industry in the international
markets.209 Congress then passed the Drug Export Amendments Act of 1986, which expands the FDA’s
201Id.
202Id.
203The Orphan Drug Act of 1983, Pub. L. No. 97-414, 96 Stat. 2049 (1983) (amending Pub. L. No. 75-717, 52 Stat 1040
(1938)) (codiﬁed principally at 21 U.S.C. §§ 360aa – 360ee (2003)).
204Id. at § 2(a), adding § 525(a) (codiﬁed at 21 U.S.C § 360aa(a) (2003)).
205Id. at § 2(a), adding § 526(a)(1) (codiﬁed at 21 U.S.C § 360bb(a)(1) (2003)). Id. at § 527(b) (codiﬁed at 21 U.S.C §
360cc(b) (2003)), provides that the FDA shall not approve a drug application for an orphan drug for seven years after it has
already approved an orphan drug treating the same medical condition the new orphan drug proposes to treat, unless the ﬁrst
applicant consents, or cannot produce enough of the drug to meet the needs of those with the rare disease.
206Id. at § 5(a) (codiﬁed as amended 21 U.S.C. 360ee(a) (2003)).
207The Food and Drug Administration Revitalization Act, Pub. L. 101-635, Title III, 104 Stat. 4584 (1990) (amending Pub.
L. No. 75-717, 52 Stat 1040 (1938)) (codiﬁed at 21 U.S.C. § 394 (2003)).
208FDA Guidance for Industry on: Exports and Imports Under the FDA Export Reform and Enhancement Act of 1996, FDA,
U.S. Department of Health and Human Services, (February 1998), http://www.fda.gov/opacom/fedregister/frexport.html.
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25enforcement power with respect to drugs being exported.210 Such drugs must meet certain criteria in order
to be exported,211 and can only be exported to certain countries.212 Accordingly, the FDA is mandated
to review and approve applications for the export of unapproved drugs, to assure that they comply with
this Act.213 There were however a few problems with these amendments. The process of approval of drugs
for export was criticized for being too lengthy.214 The amendments were criticized for requiring drugs to
be approved for export, especially when the importing countries had their own health authorities, or had
already approved the drug product.215 The export of unapproved drugs was conﬁned to 21 countries, and
although the FDA could add more countries to the list, it lacked an “administrative mechanism” to accom-
plish this.216 In addition, the law’s requirement that the unapproved drug being exported must have the
same active ingredient as a drug for which approval is being “actively pursued,” in the U.S. created some
problems. It was not clear “the degree to which the active ingredient had to be the same or how actively
the manufacturer had to be seeking approval.”217 Congress later passed the FDA Export Reform and En-
hancement Act of 1996 to address these issues. This Act created an administrative mechanism for adding
countries onto the list.218 The act replaced the export approval process with a simple notiﬁcation to the
FDA.219 The Act frees from regulation the export of drugs for investigational use, or for further processing
in anticipation of market authorization in any of the listed importing countries.220 The Act also provides for
the export of unapproved drugs when the exporter provides the FDA with credible scientiﬁc evidence of the
210The Drug Export Amendments Act of 1986, Pub. L. No. 99-660, 100 Stat. 3743 (1986) (amending Pub. L. No. 75-717, 52
Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. § 382 (2003))
211See id. at § 102, adding § 802(b)(1), (repealed 1996), for requirements that must be met before a drug can be approved by
the FDA for exportation.
212See id. at § 102, adding § 802(b)(4)(B) (codiﬁed as amended 21 U.S.C. § 382(b)(1)(B) (2003)), for the criteria used to
select which countries get to be on the list of those that can receive drug exports from the U.S., see Section 802 (b)(4)(B).
213Id. at § 102, adding § 802(b)(3) (codiﬁed as amended 21 U.S.C. § 382(b)(3) (2003)).
214FDA Guidance for Industry on, supra note 208.
215Id.
216Id.
217Id.
218The FDA Export Reform and Enhancement Act of 1996, Pub. L. 104-134, § 2102(a), adding § 802 (b)(1)(C) 110 Stat..
1321-313 (1996) (amending Pub. L. No. 75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 381, 382 (2003)).
219Id. at § 2012(a), adding § 802(g) (codiﬁed at 21 U.S.C § 382(g) (2003)).
220Id. at § 2012(a), adding § 802(c) & (d) (codiﬁed at 21 U.S.C § 382(c) & (d) (2003)).
26drug’s safety and eﬀectiveness, and the importing country requests the approval of the export of that drug
to it.221 The exporters of drugs that treat tropical diseases still need to get FDA approval to export those
drugs. They are also required to report any information they receive indicating adverse reactions to such
drugs.222 The FDA was also empowered to prohibit the export of drugs intended to treat tropical diseases
if it determines that such export presents an “imminent hazard.”223
Congress made some ﬁndings that resulted in its passage of the Prescription Drug Marketing Act of 1987.224
Congress found that there were inadequate safeguards “to prevent the introduction and eventual retail sale of
substandard, ineﬀective, or even counterfeit drugs.”225 It also found that there was a wholesale submarket,
called the “diversion market,” that interfered with FDA regulation of prescription drugs and made it diﬃ-
cult to ascertain the true sources of those drugs.226 Congress found that there was a massive reimportation
of drugs into the U.S. as “American goods returned,” that presented a health risk from possible adulter-
ation during foreign handling and shipping.227 It also found that the drug reimports had an established
market that provided a “cover for the importation of foreign counterfeit drugs.”228 It was found that the
“system of providing drug samples to physicians through manufacturers’ representatives had been abused
for decades and had resulted in the sale to consumers of misbranded, expired, and adulterated pharma-
ceuticals.”229 These ﬁndings prompted Congress to pass the Prescription Drug Marketing Act of 1987 to
221Id. at § 2012(a), adding § 802(b)(3) (codiﬁed at 21 U.S.C § 382(b)(3) (2003)).
222Id. at § 2012(a), adding § 802(e)(2) (codiﬁed at 21 U.S.C § 382(e)(2) (2003)).
223Id. at § 2012(a), adding § 802(e)(3)(B) (codiﬁed at 21 U.S.C § 382(e)(3)(B) (2003)).
224The Prescription Drug Marketing Act of 1987, Pub. L. No. 100-293, 102 Stat. 96-99 (1988) (amending Pub. L. No. 75-717,
52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 353, 381 (2003))
225Id. at § 2(2) (appears as a note to 21 U.S.C. § 353 (2003)).
226Id. at § 2(3) (appears as a note to 21 U.S.C. § 353 (2003)).
227Id. at § 2(4) (appears as a note to 21 U.S.C. § 353 (2003)).
228Id. at § 2(5) (appears as a note to 21 U.S.C. § 353 (2003)).
229Id. at § 2(6) (appears as a note to 21 U.S.C. § 353 (2003)).
27“assure the integrity of the distribution system for prescription drugs.”230 This Act restricts the importa-
tion of prescription drugs that had previously been exported from the U.S.,231 and also restricts the sale
and distribution of prescription drug samples.232 The FDA is mandated to license wholesale distributors of
prescription drugs in interstate commerce and to prescribe regulations establishing the terms and conditions
for such licensing.233 The Act also provides for severe penalties for its violation.234
According to Ed Scarbrough, Ph.D., director of the Oﬃce of Food Labeling in the FDA’s Center for Food
Safety and Applied Nutrition, the food industry’s attitude before 1980, was “Nutrition won’t sell food. It’s
price, taste and convenience.” However, in the 1980s Scarbrough noted that nutrition became a big factor
in product sales prompting the industry to start making nutrition claims on food.235 Two reports, “the
1988 Surgeon General’s Report on Nutrition and Health, and the 1989 National Research Council’s Diet
and Health: Implications for Reducing Chronic Disease Risk, concluded that evidence substantiates an as-
sociation between diet and risk of chronic disease and recommended some dietary changes.” The National
Research Council’s report actually recommended amounts of what it considered healthy intakes for certain
nutrients.236 However, food labels did not have adequate information to assist consumers to make informed
healthy choices.237 The Nutrition Labeling and Education Act of 1990 was passed to prescribe nutrition
labeling for foods.238 The Act prescribes the nutrition information that must be on the label of a food.239
The Nutrition Labeling and Education Act of 1990 gives the FDA the authority to require through regula-
230Id. at § 2(2) (appears as a note to 21 U.S.C. § 353 (2003)).
231Id. at § 3 (codiﬁed at 21 U.S.C. § 381(d)(1) (2003)).
232See id. at § 4 (codiﬁed at 21 U.S.C. § 353(c) (2003)), for sales restrictions, and id. at § 5 (codiﬁed at 21 U.S.C. § 353(d)
(2003)), for distribution restrictions.
233Id. at § 6, adding § 503(e)(2)(B) (codiﬁed at 21 U.S.C. § 353(e)(2)(B) (2003)).
234See id. at § 7 (codiﬁed at 21 U.S.C. § 333(b)(1) (2003)), for the penalties provided for violation of various sections of the
Act.
235Paula Kurtzweil, Good Reading for Good Eating, http://www.fda.gov/fdac/special/foodlabel/goodread.html. (Paula
Kurtzweil is a member of FDA’s public aﬀairs staﬀ).
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238The Nutrition Labeling and Education Act of 1990, Pub. L. No. 101-535, 104 Stat. 2353 (1990) (amending Pub. L. No.
75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. § 343 (2003)).
239Id. at § 2(a) adding § 403 (q)(1) (codiﬁed at 21 U.S.C. § 343(q)(1) (2003)).
28tions, that any of the required nutrition information be highlighted on the label, if it is deemed necessary to
help consumers make informed dietary decisions.240 The FDA is also authorized to add or remove a nutrient
from the list of required nutrition information.241 The FDA is authorized to issue nutrition information
guidelines to retailers of raw agricultural commodities and seafood. It is also up to the FDA to designate
the 20 varieties (or more if necessary) of vegetables, of fruit and of raw ﬁsh most frequently consumed, that
have to observe the nutrition information guidelines.242 Further, pursuant to a determination made every
two years, if the FDA ﬁnds that retailers have not substantially complied with the guidelines, it is authorized
to make such nutrition information requirements mandatory on every retailer selling raw agricultural com-
modities or raw ﬁsh.243 The FDA is authorized to regulate claims of relationships between a nutrient whose
information is required on the label, and a disease or health-related condition.244 The Act authorizes the
FDA to promulgate regulations deﬁning terms used to describe the level of a nutrient in a food, and require
that such terms should not be used in a way that is misleading or inconsistent with their deﬁnitions.245 The
FDA’s nutrition information regulations preempt state laws requiring such information,246 unless they are
exempted from such preemption.247 John Vanderveen, Ph.D., director of FDA’s Oﬃce of Plant and Dairy
Foods and Beverages, observed that this Act made the “United States the ﬁrst country in the world to have
mandatory nutrition labeling and to allow health claims on food labels.”248
In 1989, the FDA discovered that a few generic drug manufacturers had engaged in unlawful conduct:
240Id. at § 2(a) adding § 403(q)(1)(A) (codiﬁed at 21 U.S.C. § 343(q)(1)(A) (2003)).
241Id. at § 2(a) adding § 403(q)(2)(A) (codiﬁed at 21 U.S.C. § 343(q)(2)(A) (2003)).
242Id. at § 2(a) adding § 403(q)(4)(B) (codiﬁed at 21 U.S.C. § 343(q)(4)(B) (2003)), and § 403(q)(4)(D)(ii) (codiﬁed at 21
U.S.C. § 343(q)(4)(D)(ii) (2003)).
243Id. at § 2(a) adding § 403(q)(4)(D)(i) (codiﬁed at 21 U.S.C. § 343(q)(4)(D)(i) (2003))..
244Id. at § 3(a) adding § 403(r)(3) (codiﬁed at 21 U.S.C. § 343(r)(3) (2003)), in order to make such claims, the FDA requires
that they be “based on the totality of publicly available scientiﬁc evidence..., that there is signiﬁcant scientiﬁc agreement, among
experts qualiﬁed by scientiﬁc training and experience to evaluate such claims, that the claim is supported by such evidence.”
245Id. at § 3(b)(1)(A) (appears as a note to 21U.S.C. § 343 (2003)), terms used to describe nutrient level in a food include
“free, low, light or lite, reduced, less and high”
246Id. at § 6(a) (codiﬁed at 21 U.S.C. § 343-1(a) (2003)).
247See id. at 6(b) (codiﬁed at 21 U.S.C. § 343-1(b) (2003)), for the procedure and conditions necessary to receive exemption
from preemption.
248Kurtzweil, supra note 233.
29“falsifying data on drug formulations and illegally giving money to FDA chemists reviewing their drug
applications–to gain preferential treatment.”249 This was done to avoid FDA’s regulations.250 In response
to this “conﬁdence-shaking discovery,” Congress passed the Generic Drug Enforcement Act of 1992 to ensure
the integrity of abbreviated drug applications.251 This Act mandates the FDA to debar entities and indi-
viduals that have been convicted of certain felonies, from participating in the submission of any abbreviated
drug application, or from assisting persons that have an approved or pending drug application.252 The FDA
is authorized to suspend the distribution of a drug if it ﬁnds that the applicant has engaged in the proscribed
conduct.253 The FDA also has the authority to withdraw approval of an abbreviated drug application if such
approval was obtained fraudulently, or the applicant cannot conform with the application‘s requirements.254
In addition to these measures, “the FDA also tightened its regulatory processes, for better veriﬁcation of
data used to support approval decisions.”255
The idea of charging applicants fees for reviewing their drug applications ﬁrst came up in 1971 and then
again in 1982, both times being repudiated or failing to garner adequate support.256 In 1992, FDA Com-
missioner David A. Kessler, M.D., testiﬁed before Congress during budget proceedings for the 1993 ﬁscal
year. He impressed upon Congress the signiﬁcance of user fees to the functioning of the FDA, and urged
Congress to give the issue due consideration.257 The FDA and the pharmaceutical industry cooperated to
“create performance goals and determine what fees would be needed to reach those goals.”258 Previous
249Tamar Nordenberg, Inside FDA: Barring People from the Drug Industry, http://www.fda.gov/fdac/features/1997/297 debar.html.
(Tamar Nordenberg is a staﬀ writer for FDA Consumer).
250Id.
251Id. See also The Generic Drug Enforcement Act of 1992, Pub. L. No. 102-282, 106 Stat. 149 (1992) (amending Pub. L.
No. 75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 335a, 335c (2003)).
252See, Pub. L. No. 102-282, supra note 251, at § 2, adding § 306, (codiﬁed at 21 U.S.C. § 335a (2003)), for the various felony
convictions that can result in debarment, the debarment period, and the procedure for termination of debarment.
253Id. at § 2, adding § 306(g) (codiﬁed at 21 U.S.C. § 335a(g) (2003)). See also § 306 (h) (codiﬁed at 21 U.S.C. § 335a(h)
(2003)), for the procedure for termination of a suspension.
254Id. at § 4, adding § 308(a) (codiﬁed at 21 U.S.C. § 335c(a) (2003)).
255Nordenberg, supra note 249.
256John Henkel, User Fees to Fund Faster Reviews, FDA Consumer special report (January 1995).
http://www.fda.gov/fdac/special/newdrug/userfees.html.
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30discussions of user fees included many products regulated by the FDA, but the ﬁnal proposal only comprised
of prescription drugs and certain biologics.259 Congress then passed the Prescription Drug User Fee Act of
1992 to “make additional funds available for the purpose of augmenting the resources of the FDA that are
devoted to the process for review of human drug applications.”260 This Act authorizes the FDA to assess
and collect fees from human drug applicants.261 The Act also authorizes the FDA to assess and collect
fees that must be paid annually by prescription drug establishments and also for every prescription drug
product.262 It also sets forth a payment schedule and fee schedule for drug application fees, prescription
drug establishments fees and prescription drug product fees.263 Such fees are mandatory and any application
is considered incomplete if they are not paid.264 The Act provides that such fees are to be used only for
the review of human drug applications.265 The FDA is also mandated to increase the total fee revenues to
reﬂect an increase in the Consumer Price Index, and to adjust the fees to meet the revenue increase.266 The
FDA is authorized to waive or reduce fees if it ﬁnds it necessary to protect the public health or if it would
cause an innovation barrier.267
Even though the FDCA did not allow uses for animal drugs other that the uses they had been approved
for (“extra-label” uses), the FDA “exercised regulatory discretion regarding extra-label use of animal drugs
provided certain criteria were met.”268 The FDA issued a Compliance Policy Guide that set forth these
259Id.
260The Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (1992) (amending Pub. L. No. 75-717,
52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 379f, 379g, 379h (2003)). See also id. at § 102 (appearing in a note
to 21 U.S.C. § 379g (2003)), for Congress’ ﬁndings that set forth the purposes of this act.
261Id. at § 103 adding § 736(a) (codiﬁed as amended 21 U.S.C. § 379h(a) (2003)).
262See id. at § 103 adding § Section 736(a)(2) (codiﬁed as amended 21 U.S.C. § 379h(a)(2) (2003)), for more information
regarding the prescription drug establishment fee and id. at § 736(a)(3) (codiﬁed as amended 21 U.S.C. § 379h(a)(3) (2003)),
for more information regarding the prescription drug product fee.
263See id. at § 103 adding § 736(a)(1)(B) (repealed 1997), for the payment schedule and § 736(b)(1) (repealed 1997) (replaced
by 21 U.S.C. § 379h(b) (2003)), for the fee schedule.
264Id. at § 103 adding § 736(e) (codiﬁed as amended 21 U.S.C. § 379h(e) (2003)).
265Id. at § 103 adding § 736(g) (codiﬁed as amended 21 U.S.C. § 379h(g) (2003)).
266Id. at § 103 adding § 736(c) (codiﬁed as amended 21 U.S.C. § 379h(c) (2003)).
267Id. at § 103 adding § 736 (d) (codiﬁed as amended 21 U.S.C. § 379h(d) (2003)).
268Draft CPG on Use of Medicated Feeds for Minor Species Available, CVM Update, FDA Center for Veterinary
Medicine (August 26, 1999), http://www.fda.gov/cvm/index/updates/minorelu.html.
31criteria, which then largely became part of the Animal Medicinal Drug Use Clariﬁcation Act of 1994.269
This Act was passed to “clarify the application of the Act with respect to alternate uses of new animal
drugs.”270 This Act authorizes the FDA to make regulations establishing conditions for uses of an animal
drug other than the use it was approved for.271 The FDA can also establish safe levels for an animal drug
residue for such authorized diﬀerent use, if there’s a public health risk involved.272 If no analytical method
has been developed to detect residues above the safe level, then the FDA has the authority to prohibit such
use.273
Prior to 1994, the FDA subjected dietary supplements to the same regulatory requirements as foods.274 The
FDA therefore “ensured that they were safe and wholesome, and that their labeling was truthful and not
misleading.”275 However, Congress passed the Dietary Supplements Health and Education Act of 1994 to
“establish standards with respect to dietary supplements.”276 The act empowers the FDA to report dietary
supplement violations to a U.S. attorney for the institution of civil proceedings. In such proceedings, the
U.S. has the burden of proof to show that a dietary supplement is adulterated, misbranded or that its label
is false or misleading.277 The Act requires dietary supplement manufacturers to notify the FDA about any
claim of a relationship between a nutrient and a disease or health condition.278 The FDA is given the au-
thority to issue an order “prescribing the conditions under which a new dietary ingredient under its intended
conditions of use will reasonably be expected to be safe.”279 Therefore, other than when a new dietary
269Id.
270The Animal Medicinal Drug Use Clariﬁcation Act of 1994, Pub. L. 103-396,108 Stat. 4153 (1994) (amending Pub. L. No.
75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. § 360b (2003)).
271Id. at § 2(a), adding § 512(a)(4)(A) (codiﬁed at 21 U.S.C. § 360b(a)(4)(A) (2003)).
272Id. at § 2(a), adding § 512(a)(4)(B) (codiﬁed at 21 U.S.C. § 360b(a)(4)(B) (2003)).
273Id. at § 2(a), adding § 512(a)(4)(D) (codiﬁed at 21 U.S.C. § 360b(a)(4)(D) (2003)).
274Dietary Supplement Health and Education Act of 1994, Center for Food Safety and Applied Nutrition, U. S. Food
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276The Dietary Supplements Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994) (amending Pub.
L. No. 75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 342(f) & (g), 343-2, 343(r) & (s), 350b (2003)).
277Id. at § 4 (codiﬁed at 21 U.S.C. § 342(f)(1) (2003)).
278See id. at § 6 (codiﬁed at 21 U.S.C. § 343(r)(6) (2003)), for requirements that must be met before such claims may be
made.
279Id. at § 8, adding § 413(b) (codiﬁed at 21 U.S.C. § 350b(b) (2003)).
32ingredient is involved, dietary supplements do not need premarket approval.280 The FDA is also authorized
to promulgate regulations prescribing good manufacturing practices for the dietary supplements industry.281
Due to a collaboration between the FDA, a coalition of animal industry groups, and manufacturers of an-
imal drugs, Congress passed the Animal Drug Availability Act of 1996 to increase the number of animal
drugs on the market.282 It sets the conditions under which the FDA can decline to approve applications
for animal drugs with multiple active ingredients or an animal drug suggested for use in combination with
another animal drug (“combination drugs”).283 The FDA is authorized to pass regulations specifying the
information to be included in a “veterinary feed directive,” supervising the use of a “veterinary feed directive
drug.”284 Distributors of animal feed containing a veterinary feed directive drug are required to notify the
FDA of their name and place of business before initiating distribution. They are also required to keep records
that are subject to inspection by the FDA.285 The Act authorizes the FDA to pass regulations establishing
tolerances for new animal drug residues in animals being imported into the U.S.286 The Act also requires
manufacturers of animal feeds containing new animal drugs to obtain a license from the FDA authorizing
such manufacture.287 A single license for each manufacturer eliminates the previous requirement that each
manufacturer obtain multiple “Medicated Feed Applications” for each feed mill.288 This Act “reﬂects the
spirit of the White House program to reinvent the government (REGO) by reducing regulatory burdens on
280Overview of Dietary Supplements, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Adminis-
tration (January 3, 2001), http://www.cfsan.fda.gov/∼dms/ds-oview.html.
281Public Law 103-417, supra note 276, at § 9 (codiﬁed at 21 U.S.C. § 342(g) (2003)),
282Jarilyn Dupont, Animal Drug Availability Act (ADAA) of 1996: Legislative History of ADAA and Import Tolerances
(January 22, 2002), http://www.fda.gov/ohrms/dockets/ac/02/slides/3816s1 01 DUPONT.ppt. (Jarily Dupont is the Senior
Legislative Counsel at the FDA).
283The Animal Drug Availability Act of 1996, Pub. L. No. 104-250, 110 Stat. 3151 (1996) (amending Pub. L. No. 75-717, 52
Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 360b, 354 (2003)). See id. at § 2(c) adding § 512(d)(4)(A) (codiﬁed at
21 U.S.C. § 360b(d)(4)(A) (2003)).
284Id. at § 5(b), adding § 504(a)(1) (codiﬁed at 21 U.S.C. § 354(A)(1)(2003)) ( providing that “a drug intended for use in or on
animal feed which is limited by an approved application ...to use under the professional supervision of a licensed veterinarian
is a veterinary feed directive drug.”
285Id. at § 5, adding § 504(a)(3)(b) (codiﬁed at 21 U.S.C. § 354(a(3)(B) (2003)).
286Id. at § 4, adding § 512(a)(6) (codiﬁed at 21 U.S.C. § 360b(a)(6) (2003)).
287Id. at § 6(b), amending § 512(m)(1) (codiﬁed at 21 U.S.C. § 360b(m)(1) (2003)).
288Feed Mill Licensing Now a Reality, CVM Update, FDA Center for Veterinary Medicine (November 5, 1996),
http://www.fda.gov/cvm/index/updates/update11596.html.
33the animal health industry without undermining the safety of animal drug products.289
Congress passed the Food and Drug Administration Modernization Act (FDAMA) of 1997 to improve FDA’s
regulation of food, drugs, devices and cosmetics.290 Through this Act, “Congress aﬃrmed FDA’s role as
a protector and promoter of the public health of American citizens, endorsed many actions that FDA had
already taken to streamline its operations, and added substantial new obligations.”291 This Act renewed the
Prescription Drug User Fee Act of 1992 for an additional ﬁve years.292 It also exempted from the payment
of user fees, orphan drugs and supplemental drug applications that propose a new use in the pediatric popu-
lation.293 The FDA is authorized to request applicants with pending applications for new drugs, to conduct
pediatric studies to determine if the new drug can be used in the pediatric population. The FDA can also
make such requests to holders of approved drug applications “for which additional pediatric information may
produce health beneﬁts in the pediatric population.”294 The Best Pharmaceuticals for Children Act of 2002
passed later by Congress, provides more details with respect to the conduct of pediatric studies and pediatric
drug approvals.295 The FDA is authorized by FDAMA to designate a new drug as a “fast track product”
if it is intended to treat a serious or life-threatening condition whose medical needs are unmet, in order for
it to receive expedited review.296 The sponsor for such a fast track product has to conduct post-approval
studies and submit copies of all promotional material of the product before and after approval.297
289President Signs Animal Drug Availability Act, CVM Update, FDA Center for Veterinary Medicine (October 18,
1996), http://www.fda.gov/cvm/index/updates/adaa.html.
290The Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296 (1997) (amending
Pub. L. No. 75-717, 52 Stat 1040 (1938)) (making amendments to most sections of the FDCA)
291A Message to FDA Stakeholders, FDA Modernization Act of 1997, FDAMA Communications,
http://www.fda.gov/oc/fdama/comm/message.htm.
292Public Law 105-115, supra note 290, at § 101(3) (appears as a note to 21 U.S.C. §379g (2003)).
293Id. at § 103(a)(2)(C) (codiﬁed at 21 U.S.C. § 379h(a)(1)(E) (2003)).
294Id. at § 111, adding § 505A(a) & (c) (codiﬁed at 21 U.S.C. § 355a(b) & (c) (2003)). See also id. at § 505A(d) (codiﬁed at
21 U.S.C. § 355a(d) (2003)), for more information on the conduct of pediatric studies.
295The Best Pharmaceuticals for Children Act of 2002, Pub. L. No. 107-109, 115 Stat 1408 (2002) (amending Pub. L. No.
75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 355a, 379h, 393a and at 42 U.S.C. § 284m (2003)). See id.
at § 6 (codiﬁed at 21 U.S.C. § 393a), providing for the establishment of an Oﬃce of Pediatric Therapeutics within the FDA to
handle all FDA activities that involve pediatric issues.
296Public Law 105-115, supra note 290, at § 112, adding § 506(a) (codiﬁed at 21 U.S.C. § 356(a) (2003))..
297Id. at § 112, adding § 506(b)(2) (codiﬁed at 21 U.S.C. § 356(b)(2) (2003)).
34FDAMA requires the FDA to approve a supplemental drug application for a major manufacturing change
from the process previously approved, before the drug made with the change can be distributed.298 The FDA
is authorized to issue guidelines on when a drug applicant can submit an abbreviated study report instead
of a full report.299 The FDA is also authorized to establish and use scientiﬁc advisory panels to provide the
FDA with “expert scientiﬁc advice and recommendations ...regarding a clinical investigation of a drug or
the approval for marketing of a drug.”300 FDAMA eliminates the requirement to get FDA certiﬁcation of
drugs containing insulin or antibiotics.301 The FDA is authorized to promulgate regulations setting forth the
conditions and manner in which drugs can be compounded by a licensed pharmacist or licensed physician.
302 Such regulations would also include a list of drug substances that have not been approved by the FDA,
or which do not have a monograph, that may be used in compounding.303 Licensed pharmacists and licensed
physicians can advertise the compounding service, but cannot advertise the compounding of any particular
drug, class of drug, or type of drug.304 FDAMA requires a manufacturer that is the only manufacturer
of a drug that is life-supporting, life-sustaining, or is used in the prevention of a debilitating disease or
condition, to notify the FDA of the discontinuance of such manufacture.305 The FDA is authorized to give
review priority to medical devices that are to be used in the treatment or diagnosis of a life-threatening or
debilitating diseases.306
FDAMA authorizes the FDA to recognize and withdraw recognition of performance standards for medical
devices that have been established by a nationally or internationally recognized standard development orga-
298See id. at § 116, adding § 506A(c) (codiﬁed at 21 U.S.C. § 356a(c) (2003)), for the changes that would be considered major
and that would thus required FDA approval.
299Id. at § 118 (appears at a note to 21 U.S.C. § 355 (2003)).
300Id. at § 120 (codiﬁed at 21 U.S.C. § 355(n) (2003)).
301Id. at § 125 (repeals previous sections that required the certiﬁcation of drugs containing insulin or antibiotics).
302Id. at § 127, adding § 503A(b)(1)(A) (codiﬁed at 21 U.S.C. § 353a(b)(1)(A) (2003)).
303Id. at § 127, adding § 503A(d)(2) (codiﬁed at 21 U.S.C. § 353a(d)(2) (2003)).
304Id. at § 127, adding § 503A(c) (codiﬁed at 21 U.S.C. § 353a(c) (2003)).
305Id. at § 131, adding § 506C(a) (codiﬁed at 21 U.S.C. § 356c(a) (2003)).
306See id. at § 202 (codiﬁed at 21 U.S.C. § 360e(d)(5) (2003)), these devices have to represent breakthrough technologies, have
no approved alternatives, or have signiﬁcant advantages over existing approved alternatives.
35nization.307 The FDA is also authorized to accredit persons to review reports and make recommendations to
the FDA regarding the initial classiﬁcation of medical devices.308 The FDA is authorized to pass regulations
setting forth the conditions under which a food additive that is a food contact may be safely used.309 A
“food contact substance” is “any substance intended for use as a component of materials used in manu-
facturing, packing, packaging, transporting, or holding food if such use is not intended to have a technical
eﬀect in such food.”310 FDAMA requires manufacturers of food contact substances to provide only a simple
notiﬁcation to the FDA identifying the substance, its intended use and a determination that such use is
safe, before introduction into interstate commerce. If the FDA determines that a food contact substance
has not been shown to be safe, it can object to the notiﬁcation, “which shall constitute ﬁnal agency action
subject to judicial review.” 311 FDAMA requires the manufacturer of a drug or device to have submitted a
supplemental application for a new use before circulating information regarding the safety and eﬀectiveness
of such new use to certain individuals and entities.312 The FDA has to review a copy of the information
before it is circulated and can require further objective information regarding the safety or eﬀectiveness of
such new use.313 The FDA is also authorized to order a cessation of circulation of the information if it
determines that the information fails to conform to the requirements established by FDAMA.314
FDAMA empowers the FDA to authorize the use of unapproved investigational drugs or devices for the
treatment of a serious disease or condition in emergency situations, or pursuant to an “expanded access
protocol.”315 FDAMA mandates the FDA to establish and publish regulations setting forth standards
307Id. at § 204 (codiﬁed at 21 U.S.C. § 360d(c) (2003)).
308See id. at § 210, adding § 523(a)(3) (codiﬁed at 21 U.S.C. § 360m(a)(3) (2003)), for activities the accredited persons may
not perform, and Section 523(b) for the procedure, qualiﬁcations and withdrawal of accreditation.
309Id. at § 309(a), adding § 409(a)(3) (codiﬁed at 21 U.S.C. § 348(a)(3) (2003)).
310Id. at § 309(b)(2), adding § 409(h)(6) (codiﬁed at 21 U.S.C. § 348(h)(6) (2003)).
311Id. at § 309(b)(2), adding § 409(h)(2) (codiﬁed at 21 U.S.C. § 348(h)(2) (2003)).
312Id. at § 401(a), adding § 551(a) and § 554(a) (codiﬁed at 21 U.S.C. § 360aaa(a) and § 360aaa-3(a) respectively (2003)).
313Id. at § 401(a), adding § 551(c) (codiﬁed at 21 U.S.C. § 360aaa(c) (2003)).
314Id. at § 401(a), adding § 555(b)(1) (codiﬁed at 21 U.S.C. § 360aaa-4(b)(1) (2003)).
315Id. at § 402, adding § 561(a) and (c) (codiﬁed at 21 U.S.C. § 360bbb(a) (2003)).
36for the timely review of supplemental applications submitted for approved articles under the FDCA.316
The FDA is also mandated to pass regulations establishing a procedure for the resolution of any scientiﬁc
controversies between the FDA and an applicant requesting any FDA action.317 The FDA is also authorized
to develop guidelines, after public participation, “setting forth initial interpretations of a statute or regulation,
changes in interpretation or policy that are of more than a minor nature, complex scientiﬁc issues, or highly
controversial issues.”318 The FDA is mandated to establish an information system to monitor the status and
progress of each application submitted to it requesting its action.319 The FDA is authorized to promulgate
regulations restricting the sale of mercury intended to be used as a drug or dietary supplement if it determines
that such use poses a threat to human health.320 The FDA is authorized to contract for expert review to
obtain recommendations with respect to applications submitted to the FDA.321 FDAMA also requires foreign
establishments “engaged in the manufacture, preparation, propagation, compounding or processing of a drug
or device that is imported into the U.S.,” to register with the FDA.322
Congress passed the Medicine Equity and Drug Safety Act of 2000 in order to make accessible to Americans
prescription drugs available in other countries at signiﬁcantly lower prices than in the U.S.323 This Act autho-
rizes the FDA to promulgate regulations allowing pharmacists and wholesalers to import prescription drugs
into the U.S.324 Such imported prescription drugs have to meet the safety and eﬀectiveness requirements
316Id. at § 403(a) (appears as a note to 21 U.S.C. § 371 (2003)).
317Id. at § 404, adding § 562 (codiﬁed at 21 U.S.C. § 360bbb-1 (2003)).
318Id. at § 405, adding § 701(h)(1)(C) (codiﬁed at 21 U.S.C. § 371(h)(1)(C) (2003)).
319Id. at § 407(a), adding § 741 (codiﬁed at 21 U.S.C. § 379k (2003)).
320Id. at § 413(c)(2) (appearing as note to 21 U.S.C. § 393 (2003)).
321Id. at § 415, adding § 907(a)(1) (codiﬁed at 21 U.S.C. § 397(a)(1) (2003)).
322Id. at § 417, amending § 510(i) (codiﬁed at 21 U.S.C. § 360(i) (2003)).
323The Medicine Equity and Drug Safety Act of 2000, Pub. L. 106-387, 114 Stat 1549A-35 (2000) (amending Pub. L. No.
75-717, 52 Stat 1040 (1938)) (codiﬁed at 21 U.S.C. § 384 (2003)).
324Id. at § 745(c), adding § 804(a) (codiﬁed at 21 U.S.C. § 384(a) (2003)).
37of the FDCA.325 The importers are required to keep records on such importation and to provide the FDA
certain information.326 The importers are also required to test the imported shipment for authentication
and degradation and to assure that the product’s labeling conforms to FDCA requirements.327 This act also
provides that the prescription drugs can only be imported from countries that are listed or designated by the
FDA.328 The FDA is authorized to suspend the importation of a speciﬁc prescription drug if it determines
that such importation is in violation of a requirement of this Act, or that the imported product is coun-
terfeit.329 The Act however can only become eﬀective if the Secretary of the HHS determines that it will
“pose no additional risk to the public’s health and safety and [will] result in a signiﬁcant reduction in the
cost of covered products to the American consumer.”330 HHS secretary Tommy G. Thompson found that
these conditions could not be assured and declined to implement this Act upon determining that it would
“sacriﬁce public safety by opening up the closed distribution system in the United States.”331
Congress passed the Prescription Drug Import Fairness Act of 2000 to clarify the FDA’s obligations with
respect to importation of approved drugs by patients and their families.332 If the FDA decides that a certain
drug import that an individual is seeking violates the FDCA, this Act requires the FDA to provide the
individual with a detailed notice of the reasons for the decision.333
Following the terrorist attacks of September 11, 2001, Congress passed the Public Health Security and Bioter-
rorism Preparedness and Response Act of 2002. This Act was passed to “improve the ability of the U.S. to
325Id. at § 745(c), adding § 804(b)(1) (codiﬁed at 21 U.S.C. § 384(b)(1) (2003)).
326Id. at § 745(c), adding § 804(c) (codiﬁed at 21 U.S.C. § 384(c) (2003)). See id. at § 804(d) (codiﬁed at 21 U.S.C. § 384(d)
(2003)), for the information that importers need to provide the FDA.
327Id. at § 745(c), adding § 804(e) (codiﬁed at 21 U.S.C. § 384(e) (2003)).
328Id. at § 745(c), adding § 804(f) (codiﬁed at 21 U.S.C. § 384(f) (2003)).
329Id. at § 745(c), adding § 804(g) (codiﬁed at 21 U.S.C. § 384(g) (2003)).
330Id. at § 745(c), adding § 804(l) (codiﬁed at 21 U.S.C. § 384(l) (2003)).
331Michelle Meadows, Imported Drugs Raise Safety Concerns, FDA Consumer magazine (September-October 2002),
http://www.fda.gov/fdac/features/2002/502 import.html.
332The Prescription Drug Import Fairness Act of 2000, Pub. L. No. 106-387, 114 Stat 1549A-40 (2000) (amending Pub. L.
No. 75-717, 52 Stat 1040 (1938)) (codiﬁed at 21 U.S.C. § 381(g) (2003)).
333Id. at § 746(b)(3) (appears in note to 21 U.S.C. § 381 (2003)). See id. at § 746(c) (codiﬁed at 21 U.S.C. § 381(g) (2003)),
for the requirements that such a notice must meet.
38prevent, prepare for, and to respond to bioterrorism.334 Title III of this Act speciﬁcally deals with protecting
the safety and security of the food and drug supply. In order to protect against bioterrorist threats to the
food supply, the FDA is mandated to give high priority to increasing the number of inspections of food
being imported, at the ports of entry into the U.S.335 The FDA is also mandated to develop an information
management system that deals with imported foods, to enable the FDA to allocate suﬃcient funds for the
purposes of detecting purposeful adulteration of the food.336 The FDA is also charged with developing
“rapid detection” tests and sampling methodologies for the detection of intentional adulteration of food and
to conduct an assessment of the threat of intentional adulteration of food.337 This Act also adds onto the
list of persons subject to debarment, those that have been “convicted of a felony for conduct relating to
the importation into the U.S. of any food.”338 The Act also requires domestic and foreign facilities that
manufacture, process, pack or hold food for consumption in the U.S., to register with the FDA.339 Food
importers are also required to notify the FDA of any imported food shipments to facilitate inspection of such
food at the port of entry.340 The Act empowers the FDA to require that food that has been barred from
entry, bear the sign “UNITED STATES: REFUSED ENTRY,” until it is brought into compliance with the
FDCA.341 The Act also prohibits “port shopping.”342 This Act requires annual registration with the FDA
of foreign manufacturers of drugs and devices that are imported into the U.S.343 The Act requires persons
importing components of drugs and devices to be incorporated in a product intended for export, to submit
to the FDA certain detailed information, to keep records, and make reports that the FDA may require.344
334The Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Pub. L. No. 107-188, Title III, 116
Stat. 662 (2002) (amending Pub. L. No. 75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 381, 334(h), 335a(b),
350d, 350c, 374, 360, 342(h) (2003)).
335Id. at § 302(a), adding § 801(h)(1) (codiﬁed at 21 U.S.C. § 381(h)(1) (2003)).
336Id. at § 302(b) adding § 801(h)(2) (codiﬁed at 21 U.S.C. § 381(h)(2) (2003)).
337Id. at § 302(d) adding § 801(i) (codiﬁed at 21 U.S.C. § 381(i) (2003)), and id. at § 801(e).
338Id. at § 304(a)(2)(C), adding § 306(b)(3) (codiﬁed at 21 U.S.C. § 335a(b)(3) (2003)).
339Id. at § 305, adding § 415(a) (codiﬁed at 21 U.S.C. § 350d(a) (2003)).
340Id. at § 307(a), adding § 801(m)(1) (codiﬁed at 21 U.S.C. § 381(m)(1) (2003)).
341Id. at § 308(a), adding § 801(n) (codiﬁed at 21 U.S.C. § 381(n) (2003)).
342Id. at § 309, adding § 402(h) (codiﬁed at 21 U.S.C. § 342(h) (2003)).
343Id. at § 321(a), amending § 510(i)(1) (codiﬁed at 21 U.S.C. § 360(i)(1) (2003)).
344Id. at § 322(a), amending § 801(d)(3) (codiﬁed at 21 U.S.C. § 381(d)(3) (2003)).
39Congress recognized that the resources the FDA allocated to reviewing medical device applications had been
decreasing in recent years, and consequently, review was taking longer periods of time.345 Congress then
passed the Medical Device User Fee and Modernization Act of 2002 to make “additional funds available for
the purpose of augmenting the resources of the FDA that are devoted to the process for the review of devices
and the assurance of device safety and eﬀectiveness so that statutorily mandated deadlines may be met.”346
The FDA was authorized to assess user fees against premarket applications, premarket reports, supplement
applications and premarket notiﬁcations.347 The Act sets forth the fee revenue to be collected each year from
2003 to 2007, which then determines the amount of fees to be paid by persons making medical device-related
submissions to the FDA.348 Applications submitted without the required fees are considered incomplete.349
The FDA is authorized to adjust these revenues for inﬂation, workload and shortfalls from previous years.350
The Act mandates that the fees assessed are to be sued only for the review of medical device applications.351
A condition of assessing user fees, is that the FDA is expected to meat all its “performance goals.”352 The
Act also makes additional appropriations to the FDA for the purpose of conducting postmarket surveillance
of medical devices.353 This Act authorizes the FDA to accredit persons to inspect facilities that manufacture,
prepare, propagate, compound or process class II or class III devices.354 The Act also gives the FDA the
authority to debar an accredited person that is convicted of a felony for conduct relating to an inspection.355
345The Medical Device User Fee and Modernization Act of 2002: FAQs (November 7, 2002),
http://www.fda.gov/cber/mdufma/mdufma02faq.htm.
346The Medical Device User Fee and Modernization Act of 2002, Pub. L. No. 107-250, § 101(2), 116 Stat. 1588 (2002)
(amending Pub. L. No. 75-717, 52 Stat 1040 (1938)) (codiﬁed principally at 21 U.S.C. §§ 379i, 379j, 374(g), 360m(d), 335a(m)
353(g)(4), 352(f), 352(u) (2003)).
347Id. at § 102(a), adding § 738(a)(1)(A) (codiﬁed at 21 U.S.C. § 379j(a)(1)(A) (2003)). See also id. at § 738(a)(1)(B)
(codiﬁed at 21 U.S.C. § 379j(a)(1)(B) (2003)), for the exceptions to the user fee requirements of this Act.
348Id. at § 102(a), adding § 738(b) (codiﬁed at 21 U.S.C. § 379j(b) (2003)).
349Id. at § 102(a), adding § 738(f) (codiﬁed at 21 U.S.C. § 379j(f) (2003)).
350Id. at § 102(a), adding § 738(c) (codiﬁed at 21 U.S.C. § 379j(c) (2003)).
351Id. at § 102(a), adding § 738(h)(1) (codiﬁed at 21 U.S.C. § 379j(h)(1) (2003)).
352Id. at § 102(a), adding § 738(g) (codiﬁed at 21 U.S.C. § 379j(g) (2003)).
353Id. at § 104(a).
354See id. at § 201, adding § 704(g)(3) (codiﬁed at 21 U.S.C. § 374(g)(3) (2003)), for the requirements accredited persons need
to meet, the procedure of accreditation and withdrawal of accreditation.
355See Id. at § 203, adding § 306(m) (codiﬁed at 21 U.S.C. § 335a(m) (2003)), for information on the debarment period and
termination of debarment.
40The FDA’s enforcement powers have been expanded dramatically by Congress over time, through the pas-
sage of the FDCA and its amendments.
THE COURTS’ TREATMENT OF FDA ENFORCEMENT OBLIGATIONS
In a 1986 case, the Supreme Court concluded that the FDCA does not create or imply a private right of
action for individuals injured as a result of violations of the Act.356 The FDA is therefore the sole authority
that can enforce the provisions of the FDCA and ensure compliance with the FDCA. Injured individuals
can still sue a violator for negligence in state courts. A court could interpret a violation of the FDCA as
an indication of a manufacturer’s negligence in such a suit. The Fourth Circuit held in a diversity suit by
a plaintiﬀ against the manufacturer of a misbranded medical device, whose misbranding was the proximate
cause of the plaintiﬀ’s injury, that the violation of the FDCA is negligence per se in Virginia.357 The court
noted that while the FDCA does not provide a private right of action for injured consumers, it “imposes an
absolute duty on manufacturers not to misbrand their products and a breach of this duty may give rise to
civil liability.”358
Courts’ Treatment of FDA’s Inspection and Seizure Powers
The Supreme Court in United States v. Cardiﬀ 359 found that on its face, the FDCA only prohibited the
refusal to permit entry and inspection if permission had previously been granted. The Court pointed out
that Section 704 of the FDCA conditioned entry and inspection on “making request and obtaining permis-
sion,” and that on its face, the FDCA apparently gave factory managers the right to withhold permission
356Merrell Dow Pharmaceuticals, Inc. v. Thompson, 478 U.S. 804, 815 (1986).
357Orthopedic Equipment Co. v. Eutsler, 276 F.2d 455, 461 (4th cir. 1960)
358Id. at 460.
359344 U.S. 174, 176-177 (1952) - in this case, the Supreme court aﬃrmed the reversal of the respondent who had been
convicted of violating Section 301(f) of the FDCA (codiﬁed as 21 U.S.C. § 331(f)), which prohibits the refusal to permit entry
and inspection pursuant to authorized by Section 704 (codiﬁed as 21 U.S.C. § 374).
41to enter and inspect.360 This construction of the FDCA would obviously have crippled the FDA’s eﬀorts
at inspecting facilities and protecting the public health. Congress thus amended Section 704 of the FDCA
eliminating the provision requiring the FDA to obtain permission before entering at reasonable times to
inspect facilities in which food, drugs, devices, or cosmetics are manufactured, processed, packed or held for
introduction into interstate commerce, or held after such introduction.361 The Amended section 704 only
requires the FDA to give a written notice to the owner or operator of a facility before entering to inspect,
but does not require the FDA to obtain consent.362 This section “simply and unequivocally authorizes FDA
to enter and inspect certain speciﬁed premises at reasonable times.”363
Although Administrative searches are subject to the safeguards of the Fourth Amendment, and thus require
a warrant issued upon a showing of probable cause,364 there is an exception eliminating the warrant require-
ment in administrative searches of “closely regulated” industries.365 This exception is referred to as the
Colonnade-Biswell exception.366 Courts have held that warrantless searches under Section 374 of the FDCA
are valid as they fall within the Colonnade-Biswell exception.367 Courts have also consistently held that
FDA oﬃcials conducting inspections pursuant to Section 374 do not need to give Miranda warnings, as such
inspections are non-custodial.368 The Ninth Circuit has held that the FDA is not required to give advance
360Id.
361See Act of Aug. 7, 1953, Pub. L. No. 83-217, amending § 704(a), 67 Stat. 476 (amending Pub. L. No. 75-717, 52 Stat
1040 (1938)) (codiﬁed at 21 U.S.C. §§ 374 (a)(1) (2003)).
362See id.
363Daley v. Weinberger, 400 F. Supp. 1288, 1291, n.3 (E.D.N.Y. 1976), aﬀ’d, 536 F2d 519 (2nd Cir. 1976), cert. denied, 430
U.S. 930 (1977).
364See v. Seattle, 387 U.S. 541, 546 (1967), requires that an administrative search of commercial property be supported by
a search warrant. It however provides that the standard of probable cause required to obtain a warrant for an administrative
search is lower than that required for the issuance of a warrant in criminal cases.
365New York v. Burger, 482 U.S. 691, 719 n.2 (1987) cites as examples of “closely regulated” industries, the liquor industry,
ﬁrearm and ammunition sales, the coal mine industry and then ﬁnds the vehicle dismantlers industry to be closely regulated as
well.
366U.S. v. Argent Chem. Lab., 93 F.3d 572, 575-576 (9th Cir. 1996)
367U.S. v. New England Grocers Supply Co., 488 F. Supp. 230, 238 (D. Mass. 1980) The court pointed out that there was
a long history of pervasive federal regulation of the food and drug industry and thus that warrantless inspections pursuant to
§ 374 are fully consistent with the Fourth Amendment. See also Argent Chem. Lab., 93 F.3d at 575-576 (concluding that the
drug industry, including the animal drug segment, was closely regulated by the government, and thus subject of warrantless
search and seizure by the FDA). See also, U.S. v. Fogari, 1988 U.S. Dist. LEXIS 10166 (D. N.J. 1988) (concluding t the
pharmaceutical industry is a closely regulated ﬁeld and thus subject to warrantless inspection by the FDA).
368New England Grocers Supply Co., 442 F. Supp. at, 48 (D. Mass. 1977), citing, U.S. v. Thriftimart, Inc., 429 F.2d 1006
42notice of an inspection, as “the necessity and constitutionality of a surprise search was expressly upheld” by
the Supreme Court.369 Further, the FDA is not required to give a separate notice of inspection for each day
of a multiple day inspection,370 nor even specify in the notice the reason underlying the inspection or what
it expects to ﬁnd.371 The FDA is also not required to inform the party being inspected whether it intends
to proceed criminally or civilly against such party.372 In order to facilitate FDA’s inspection obligation,
Section 373 provides a method by which the FDA can obtain interstate shipment information from carriers.
The fourth circuit gave a broad interpretation to Section 373, ﬁnding that it does not exclude permissive
investigation of interstate shipment records from manufacturing facilities.373 The court also aﬃrmed the
FDA’s authority to take samples during inspections by noting that “Section 372(b) of the Act clearly con-
templates the taking of samples.”374
The Supreme court concluded that Section 304(a), which “authorizes multiple libels for condemnation of
misbranded articles upon the FDA’s ﬁnding of probable cause that a misbranded article is dangerous to
health, or that its labeling is fraudulent, or would be in material respect misleading to the injury and dam-
age of a purchaser or consumer,” does not violate due process.375 The Court found that the owner of the
seized articles has an opportunity to have a fully hearing in court when the FDA ﬁles the libel and that this
hearing satisﬁes the requirements of due process.376
Courts’ Treatment of FDA’s Power to Seek Injunctions
The First Circuit has held that there is no right to a jury trial in an action for an injunction under 21 U.S.C. §
(9th Cir. 1970) cert. denied, 400 U.S. 926 (1970) reh. denied,, 400 U.S. 1002 (1971).
369Thriftimart, Inc., 429 F.2d at 1010, citing, See v. Seatle, 387 U.S. at 545 n.6 (1967).
370See U.S. v. Durbin, 373 F. Supp 1136, 1137 (E.D. Okla. 1974).
371See Weinberger 400 F. Supp at 1291 n.3.
372Thriftimart, Inc., 429 F.2d at 1010, citing, U.S. v. Kordel, 397 U.S. 1 (1970).
373U.S. v. 75 Cases, etc., 146 F.2d 124, 127 (4th Cir. 1944), cert. denied,, 325 U.S. 856 (1945).
374Id. at 128.
375Ewing v. Mytinger & Casselberry, Inc., 339 U.S. 594, 598 (1950), reh. denied, 340 U.S. 857 (1950).
376Id. at 598.
43332(a), as the action is purely equitable in nature.377 The Ninth Circuit stated that the standards for granting
a preliminary injunction are diﬀerent where the injunction is being sought pursuant to a statute, such as the
FDCA, rather than pursuant to claims of two private litigants.378 That court declared that the FDA was
not required to show irreparable injury in seeking a statutory injunction, and that such irreparable injury
should be presumed.379 After noting that the required degree of a showing of probable success on the merits
decreases as the likelihood of irreparable harm increases, the Ninth Circuit announced that the FDA would
only need to show some chance of probable success on the merits, since the irreparable injury requirement is
presumed for statutory injunctions.380 The court also announced that in balancing the hardships that would
result from the issuance of a preliminary injunction the court has to balance the hardships that face the
party to be enjoined, against the public’s interest in consuming unadulterated food.381 It then cited Smith
v. California,382 which stated that “the usual rationale behind food and drug legislation is that ‘the public
interest in the purity of its food is so great as to warrant the imposition of the highest standard of care on
distributors.’383 In discussing the required showing of the likelihood of recurring violations, the court noted
that the cessation of violations does not itself foreclose issuance of an injunction.384 It also cautioned courts
to “beware of attempts to forestall injunctions through remedial eﬀorts and promises of reform that seem
377See U.S. v. Articles of Drug Consisting of Following: 5,906 Boxes, etc., 745 F.2d 105, 112 (1st Cir. 1984), cert. denied, 470
U.S. 1004 (1985). See also U.S v. Ellis Research Laboratories, Inc., 300 F.2d 550, 554 (7th Cir. 1962) cert. denied, 370 U.S.
918 (1962) (stating that the Seventh Amendment which preserves the right of trial by jury to “suits at common law,” does not
apply to an action for injunctive relief, which has historically been equitable in nature, with the factual issues raised triable by
the court). See also U.S. v. Louisiana, 339 U.S. 699, 706 (1950) (noting that the Seventh Amendment only applies to actions
at law and not equity actions for injuctions).
378In U.S. v. Odessa Union Warehouse Co-op, 833 F.2d 172, 174-175 (9th Cir. 1987), the court announced the factors
traditionally considered in determining whether to grant a preliminary injunction in a suit between two private litigants in the
9th circuit: (1) the likelihood of plaintiﬀ’s success on the merits; (2) the possibility of plaintiﬀ’s suﬀering irreparable injury if
relief is not granted; (3) the extent to which the balance of hardships favors the respective parties; and (4) in certain cases,
whether the public interest will be advanced by the provision of preliminary relief.
379See id. at 175, citing, Navel Orange Admin. Comm. v. Exeter Orange Co., 722 F.2d 449, 453 (9th Cir. 1983), and, SEC
v. Mgmt. Dynamics, Inc., 515 F.2d 801, 808 (2d Cir. 1975).
380See Odessa Union, 833 F.2d at 176.
381Id.
382361 U.S. 147, 152 (1959)
383See, Odessa Union, 833 F.2d at 176.
384See id., citing, City of Mesquite v. Aladdin’s Castle, Inc., 455 U.S. 283, 289 (1982).
44timed to anticipate legal action, especially when there is the likelihood of recurrence.”385 District courts
have also held that the FDA does not need to show that the food in question was injurious to health in order
to get an injunction against the shipment of such food.386
The Sixth Circuit held that a district court sitting in equity pursuant to 21 U.S.C. § 332(a),387 had the
authority to order restitution in addition to issuing an injunction.388 This court noted that the Supreme
Court in Porter v. Warner Holding Co.389 established that, unless otherwise provided by statute, all the
inherent equitable powers of the District Court are available for the proper and complete exercise of that
jurisdiction... and that restitution is within the recognized power and within the highest tradition of a court
of equity.390 The Court then went on to hold that nothing in the FDCA precludes a district court from
ordering restitution and that restitution is therefore a remedy available to a district court in appropriate
cases under 21 U.S.C. § 332(a).391
Courts’ Treatment of FDA’s Criminal and Civil Proceedings and the Pre-Prosecution Hearing Requirement
Courts have observed that if the FDCA is literally enforced, all processed food would be excluded from
interstate commerce.392 They have accordingly recognized that the FDA has the discretion to develop
“administrative working tolerances” to aid in deciding which violations to proceed against, and which to
consider de minimis.393 The Fifth Circuit has held that a court can apply a stricter standard than the FDA
385See, Odessa Union, 833 F.2d at 176, citing, U.S. v. Oregon State Medical Society, 343 U.S. 326, 333 (1952).
386See, U.S. v. Lazere, 56 F. Supp. 730, 732 (D.C. Iowa 1944). See also, U.S. v. Medwick Lab. Inc., 416 F. Supp. 832, 833
(N.D. Ill. E. Div. 1976) (noting that proof of irreparable injury or proof that the drugs are unsafe is unnecessary for injunctive
relief under the FDCA).
387This section grants the district court jurisdiction to enjoin violations of the FDCA.
388See, U.S. v. Universal Mgmt. Servs., 191 F.3d 750, 762 (6th Cir. 1999).
389328 U.S. 395, 398 and 402 (1946).
390Universal Mgmt. Servs., 191 F.3d at 761.
391Id. at 762.
392In U.S. v. 484 Bags, More or Less, 423 F.2d 839, 841 (5th Circuit 1970), the court notes that Section 343(a)(3) considers
any food adulterated if it consists in whole or in part of any ﬁlthy, putrid or decomposed substances, and then observes that
“a scientist with a microscope could ﬁnd ﬁlthy, putrid, and decomposed substances in almost any canned food we eat.
393Id. at 841, citing, U.S. v. 133 Cans of Tomato Paste, 22 F. Supp. 515, 516 (E.D. Pa. 1938) (accepting an FDA tolerance
45in ﬁnding a food adulterated, even though it is within the FDA’s tolerances. It however noted that due
to the FDCA’s purpose of protecting the public health, a court cannot apply a standard below the FDA’s
tolerances.394
Section 306 of the FDCA authorizes the FDA to issue warnings for minor violations rather than report them
for prosecution, or for the institution of libel or injunction proceedings.395 A district court has interpreted
the FDCA as vesting this discretion on the FDA and as not requiring the FDA to “establish rules and
regulations for procedures to determine whether a warning instead of a prosecution or injunction serves to
vindicate the public interest.”396
The Second Circuit has held that the FDA’s decision to institute criminal proceedings against a violator
does not preclude it from carrying out further inspections of the violator’s facility under Section 374. 397
This court noted that protecting the health and safety of the public is the FDA’s primary function, and that
the FDA should thus not be prohibited from performing this function even temporarily while a prosecution
is underway.398 The court further noted that the Supreme Court in U.S. v. Kordel399 stated that “it would
stultify enforcement of federal law to require a governmental agency such as the FDA invariably to choose
either to forgo recommendation of a criminal prosecution once it seeks civil relief, or to defer civil proceedings
pending the ultimate outcome of a criminal trial.”400
as a standard for determining whether a food in adulterated within the meaning of the FDCA).
394484 Bags, More or Less, 423 F.2d at, 842.
395This section is codiﬁed in 21 U.S.C. § 336.
396U.S. v. Hunter Pharmacy, Inc., 213 F. Supp. 323, 324 (S.D.N.Y. 1963).
397U.S. v. Gel Spice Co., 773 F.2d 427, 432 (2d Cir. 1985) cert. denied, 474 U.S. 1060 (1986).
398Id. at 432.
399397 U.S. 1, 11 (1970).
400Gel Spice Co., 773 F.2d at 432.
46A district court has upheld the constitutionality of the Drug Abuse Control Amendments Act of 1965,401
which does not require the government to show that the sale of a drug covered by the Act (depressant or
stimulant drugs) was involved in interstate commerce.402 This court found that Congress made ﬁndings
supported by evidence that the intrastate sales of LSD have a signiﬁcant eﬀect on interstate commerce.403
It then concluded that the Drug Abuse Control Amendments Act of 1965 was a constitutional exercise of
Congress’ power under the commerce clause, both on its face and as applied to purely intrastate manufacture
and sale of LSD.404 FDA could thus report for prosecution purely intrastate violations of the FDCA as
provided by this Act.
Section 305 of the FDCA, codiﬁed at 21 U.S.C. § 335, provides that “before any violation of this chapter
is reported by the Secretary to any United States attorney for institution of a criminal proceeding, the
person against whom such proceeding is contemplated shall be given appropriate notice and an oppor-
tunity to present his views, either orally or in writing, with regard to such contemplated proceeding.”
Defendants have attempted to invoke this section in seeking to enjoin criminal proceedings that have
been instituted against them before they have presented their views before the FDA. The Supreme
Court has twice held that the denial of such a hearing is not a bar to criminal prosecution. In U.S. v.
Morgan,405 the Supreme Court in interpreting a similar provision in the 1906 Act, stated that “there is
nothing in the nature of the oﬀense under the pure food law, or in the language of the statute, which
indicates that Congress intended to grant violators of this act a conditional immunity from prosecution,
or to confer upon them a privilege not given every other person charged with a crime.” The Court
conﬁrmed this holding in U.S. v. Dotterweich,406 this time interpreting the FDCA.
401See, Public Law 89-74, supra note 124.
402U.S. v. Erlin, 283 F. Supp. 396, 397 (N.D. Cal. 1968).
403Id. at 398.
404Id. at 399.
47It has further been held that the hearing provided for in Section 335 is not a “full dress trial with all the
formal attributes thereof, but only a fair opportunity [for suspects] to present their views.”407 The Seventh
Circuit also noted that the Section 335 hearing is not one that leads to a ﬁnal administrative order, subject
to statutory judicial review.408
Courts’ Treatment of FDA’s Debarment Power
21 U.S.C. 335a(a) requires the FDA to debar anyone convicted of a felony with respect to federal regulation
of drug products, from providing services in any capacity to a person that has an approved or pending drug
product application. Courts have had the occasion to rule on whether debarment under this section violates
the Double Jeopardy409 and Ex Post Facto410 Clauses of the U.S. Constitution. The D.C. Circuit announced
that the answer to this question depended on whether debarment is wholly remedial or in part a punitive
measure.411 It then concluded after analysis that it agreed with the Seventh Circuit412 that debarment
under § 335a(a) is solely remedial. Since debarment was found to be remedial, imposing debarment after
assessing civil penalties, which are punitive, against a violator does not violate the double jeopardy clause
of the Constitution.413 Likewise the court concluded that a remedial measure such as debarment cannot
violate the ex post facto clause of the Constitution.414
In a debarment notice published in the Federal Register, the FDA pointed out that debarment does not
amount to “an unconstitutional taking of the right to earn a living in the U.S.”415 It noted that Circuit
407Hunter Pharmacy, Inc., 213 F. Supp. at 323-324 (S.D.N.Y. 1963). This court also notes that this hearing is not a
prerequisite to criminal prosecution.
408Durovic v. Richardson, 479 F.2d 242, 244 (7th Cir. 1973) cert. denied, 414 U.S. 944 (1973) reh. denied, 414 U.S. 1099
(1973)
409This is found in the Fifth Amendment of the U.S. Constitution.
410This is found in Article 1, § 9 of the U.S. Constitution.
411DiCola v. FDA, 77 F.3d 504, 506 (D.C. Cir. 1996).
412Bae v. Shalala, 44 F.3d 489, 497 (7th Cir. 1995).
413DiCola, 77 F.3d at 508.
414Id. at 508. This conclusion came after the court cited DeVeau v. Braisted, 363 U.S. 144, 160 (1960) for its statement that
“the mark of an ex post facto law is the imposition of what can fairly be designated punishment for past acts” Id. at 506.
415John D. Copanos; Denial of Hearing; Final Debarment Order, 61 FR 9711, Department of Health and Human Services
(HHS), FDA, Docket No. 94N-0033, Federal Register Vol. 61, No. 48.
48Courts have held that “the expectation of employment is not recognized as a protected property interest
under the Fifth Amendment,”416 and that the Supreme Court has held that the “loss of potential proﬁt is
not a suﬃcient basis for a ‘takings’ claim.”417
Courts’ Treatment of FDA’s Publicity Powers
The D.C. district court decided that Section 375(b), which authorizes the FDA to disseminate information
regarding food, drugs, devices, or cosmetics when it determines that any such article presents an imminent
danger to health or gross deception of the consumer, was “obviously constitutional.”418 The court stated that
even without that statutory authority, the FDA could still disseminate such information to the public.419
The court also noted that in such a situation, a person can sue the FDA for damages if they can establish
that the information being disseminated is libelous.420 A district court has held that it has the power to
enjoin the FDA from issuing news releases and other public statements about a manufacturer’s product
where such publicity would prejudice a trial against such product.421
Courts’ Treatment of FDA’s Regulation of Exports and Imports
The Ninth Circuit has held that the FDCA authorizes the FDA to refuse to admit food being imported upon
416The FDA cited to Hoopa Valley Tribe v. Christie, 812 F.2d 1092, 1102 (9th Cir. 1986), and Chang v. U.S., 859 F.2d 893,
896-97 (Fed. Cir. 1988).
417Citing, Andrus v. Allard, 444 U.S. 51, 66 (1979).
418See Hoxsey Cancer Clinic v. Folsom, 155 F. Supp. 376, 378 (D. D.C. 1957).
419See id. at 378.
420See id. at 378. It might not be possible to sue the FDA for damages without its consent, as it is an agency of the federal
government and thus covered by sovereign immunity.
421U.S. v. Diapulse Mfg. Corp., 262 F. Supp. 728, 730 (D. Conn. 1967) – in this case however the court refused to issue an
injunction because the manufacturer had failed to show irreparable injury or any threat thereof.
49“the mere appearance of adulteration,” a ﬁnding of actual adulteration being unnecessary.422 Furthermore,
the court found that such a ﬁnding is not subject to judicial review.423 The Second Circuit has held that
a court has no discretion to release articles that have been condemned due to adulteration, for export to
another country.424 It stated that while articles intended for export are exempt from some of the provisions
of the FDCA, a court cannot accord condemned articles that were not originally intended for export, a
“delayed exemption for export.”425 It further noted that the FDCA provides that a court can only release
condemned articles to the owner for destruction or for being brought into compliance with the FDCA.426
Courts’ Treatment of the Intersection Between FTC False Advertising Proceedings and Libel Actions for Misbranding Under the FDCA
The fourth Circuit has stated that a proceeding before Federal Trade Commission (FTC) under 15 U.S.C.
§ 45, 52 and 53 (to enjoin the use of unfair or deceptive acts or practices and the dissemination of false
advertisements to induce the purchase of goods in interstate commerce), does not conﬂict with libel actions
under 21 U.S.C. § 334 (which invoke the power of courts to seize and condemn falsely branded goods which
have been unlawfully shipped in interstate commerce in past).427 This means that these suits can proceed
simultaneously. The court further noted that a favorable decision to the manufacturer of the goods that the
government is seeking to condemn in a libel suit, has preclusive eﬀect on the promulgation of a cease and
desist order by the FTC in a proceeding based on the same charge of misrepresentation of the character of
422Sugarman v. Forbragd, 267 F. Supp. 817, 824 (N.D. Cal. 1967), aﬀ’d, 405 F2d 1189 (9th Cir. 1968) cert. denied, 395 U.S.
960 (1969)
423Id. at 824.
424United States v. Kent Food Corp., 168 F.2d 632, 634 (2d Cir. 1948)
425Id. at 634.
426See, 21 U.S.C. § 334(d)
427U.S. v. 1 Dozen Bottles, etc., 146 F.2d 361, 363 (4th Cir. 1944).
50the goods shipped in interstate commerce.428 The Court went on to recognize that the reverse was also true:
An FTC ﬁnding that the statements made by a manufacturer are not false or misleading, has preclusive eﬀect
on a libel action seeking to condemn goods on the grounds that they are misbranded under the FDCA.429
The Second Circuit has held that a penalty for the violation of a cease and desist order issued under the
Federal Trade Commission Act430 does not preclude further remedies for violation of the FDCA. The court
stated that “the remedies are plainly cumulative and not exclusive.431
CONCLUSION
The FDCA and all its amendments have continually increased the substantive and enforcement powers
of the FDA over the years. FDA’s mission as recognized by congress, is to protect the public health by
ensuring that “foods are safe, wholesome, sanitary and properly labeled; human and veterinary drugs are
safe and eﬀective; there is reasonable assurance of the safety and eﬀectiveness of devices intended for human
use; cosmetics are safe and properly labeled; and public health and safety are protected from electronic
product radiation.”432 Further, the FDA is charged with reviewing applications for regulated products in a
prompt and eﬃcient manner, as well as working with representatives from foreign countries to “harmonize
regulatory requirements and achieve appropriate reciprocal arrangements.”433 These are very momentous
responsibilities that require the FDA to be fully equipped both ﬁnancially and in its ability to enforce its
obligations.
With increasing risk to the public health due to technological advances, it is inevitable that Congress will
continue to increase the FDA’s responsibilities and to increase its enforcement powers to enable it to meet
428Id. at 363, citing, George H. Lee Co. v. F.T.C., 111 F.2d 583, 586 (8th Cir. 1940)
4291 Dozen Bottles, etc., 146 F.2d at 363, citing, U.S. v. Willard Tablet Co., 141 F.2d 141, 143 (7th Cir. 1944).
430See, 15 U.S.C. § 45(l)
431U.S v. Five Cases of Capon Springs Water, 156 F.2d 493, 496 (2d Cir. 1946).
432Pub. L. No. 105-115, § 406(a)(2) adding § 903(b) (codiﬁed at 21 U.S.C. § 393(b), supra note 290.
433Id.
51those responsibilities. With this increase in FDA’s responsibilities, Congress will also continue to increase
its appropriations to the FDA as well as vesting it with authority to assess and collect user fees for other
products it regulates, other than drugs and medical devices, to augment its resources.
Courts have generally recognized the importance of the FDA’s mission and have construed the FDCA
liberally to enable the FDA to carry out its enforcement functions eﬀectively.434 Additionally, where the
Supreme Court interpreted the FDCA in a manner that would have made it diﬃcult for the FDA to carry
out inspections, Congress amended the FDCA to overturn that interpretation.
434See, U.S. v. Kordel, at 917 (7th Cir. 1947), aﬀ’d, 335 U.S. 345 (1948) reh. denied, 335 U.S. 900 (1948) and reh. denied,
336 U.S. 911 (1949) (noting was passed to protect the public health and should thus be given a “liberal construction” despite
the fact that it is for the most part penal and imposes criminal penalties). See also, U.S. v. 7 Jugs, etc., of Dr. Salsbury’s
Rakos, 53 F Supp 746, 752 (D. Minn 2d Div. 1944) (stating that the FDCA is one of the most important enactments under
the Commerce Clause, with its purpose of protecting the public health against adulterated and misbranded foods and drugs,
which has led courts to declare with unanimity that food and drug legislation should be given a liberal construction in order to
accomplish its remedial purposes).
52